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Abstract. The acid-mediation hypothesis, that is, the hypothesis that acid produced by tumours,
as a result of aerobic glycolysis, provides a mechanism for invasion, has so far been considered
as a relatively closed system. The focus has mainly been on the dynamics of the tumour, normal-
tissue, acid and possibly some other bodily components, without considering the effect of an external
intervention such as a cytotoxic treatment. This article aims to examine the effect that a cytotoxic
treatment has on a tumour growing under the acid-mediation hypothesis by using a simple set of
ordinary differential equations that consider the interaction between normal-tissue, tumour-tissue,
acid and chemotherapy drug.
1. Introduction
This article considers the acid-mediation hypothesis with the added interaction of a tumour treat-
ment protocol. The acid-mediation hypothesis is the assumption that tumour invasion is facilitated
by acidification of the region around the tumour-host interface caused by aerobic glycolysis, also
known as the Warburg effect [22]. This acidification creates an inhospitable environment and re-
sults in the destruction of the normal-tissue ahead of the acid resistant tumour thus enabling the
tumour to invade into the vacant region. This hypothesis was first examined by Gatenby and Gawl-
inski [10] with a system of reaction-diffusion equations that considers the interaction between the
tumour, host and acid. This article examines the acid-mediation hypothesis with the inclusion
of population competition as considered in [17] and also the effect of tumour treatment from a
cytotoxic agent such as used for chemotherapy. This will be considered here in a homogeneous
environment to gain an understanding of the reaction dynamics that could predict behaviour of an
arguably more realistic heterogeneous setting. The heterogeneous setting will be considered in a
following article that will utilise a system of reaction-diffusion equations similar to those consid-
ered in [10, 11, 17].
The effect of chemotherapy treatment has yet to be considered in a model that utilises the acid-
mediation hypothesis. We wish to present a model that addresses this unexamined question of the
interaction of the low extracellular pH of the tumour micro-environment and a cytotoxic tumour
treatment. There are however many models that consider chemotherapy and the corresponding ef-
fect on the growth of solid tumours. Continuum models have been used in which the dynamics of
total cell populations and average chemotherapy drug concentration are considered by employing
the use of ordinary differential equations (ODEs), some examples include [1, 4, 5]. There are re-
cent models that consider the addition of an immune response in a tumour cell and chemotherapy
model [2, 4] encouraged by experimental results suggesting an important impact of the host im-
mune response on the effectiveness of a chemotherapy treatment. Gatenby and Gillies [12] note
that highly acidic tumours have been shown to be resistent to anthracyclines as a result of greater
phenotypic diversity [9] which is enabled by mutagenic/clastogenic effects of acidosis. The effects
of normal cell populations in a model that considers chemotherapy have largely been neglected.
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2 A. B. Holder and M. R. Rodrigo
Hence it is an aim of this article is to determine whether the presence of normal cells can alter the
perceived effectiveness of chemotherapy.
The article is organised in the following manner. Section 2 describes the assumptions made by
the model and provides the formulation of the mathematical model being considered. In Section 3
the results are presented of a steady-state analysis for the model when treatment characterised by a
constant infusion of the chemotherapy drug is considered. The analysis of the model considering
regularly scheduled treatments occurring in cycles is presented in Section 4. A discussion of the
results of the analysis of the model considering treatment cycles is given in Section 5. Conclud-
ing remarks have been provided in Section 6. Additional results and some of the more laborious
calculations required for Sections 3 and 4 have been provided in Appendices A–C.
2. Model formulation
The basic assumptions taken into account to develop the model are
(i) Both normal and tumour cells are governed by logistic growth in the absence of any kind of
intervention [3, 4, 10];
(ii) A population competition relationship exists between the normal and tumour cells [17];
(iii) The tumour-tissue produces H+ ions as a result of aerobic glycolysis [10, 17] at a rate pro-
portional to a function of the tumour cell density;
(iv) The normal-tissue interacts with the excess H+ ions, leading to a death rate proportional to
the concentration of H+ ions [10, 17];
(v) The excess H+ ions are produced at a rate proportional to the neoplastic cell density and an
uptake term is included to take account of mechanisms for increasing pH [10];
(vi) The chemotherapy drug is infused at a rate given by a function of time. A term is included
for removal of drug from the system by metabolic processes [1, 4];
(vii) The tumour-tissue interacts with the chemotherapy drug leading to destruction of tumour-
tissue at a rate proportional to the concentration of drug [1, 4];
(viii) The chemotherapy drug concentration is decreased as a result of interaction with the tumour-
tissue [1].
Let the populations at time s (in s) be denoted by:
• N1(s), normal cell density (in cells cm−3),
• N2(s), tumour cell density (in cells cm−3),
• H(s), excess H+ ion concentration (in M),
• C(s), chemotherapy drug concentration (in M).
Consider the following model
dN1
ds
= r1N1
(
1− N1
K1
− α1N2
K2
)
︸ ︷︷ ︸
logistic growth with cellular competition
− d1HN1︸ ︷︷ ︸
normal cell death by
acid
,(1)
dN2
ds
= r2N2
(
1− N2
K2
− α2N1
K1
)
︸ ︷︷ ︸
logistic growth with cellular competition
− d2CN2︸ ︷︷ ︸
tumour death by
drug
,(2)
dH
ds
= r3f(N2)︸ ︷︷ ︸
acid production
− m3H︸ ︷︷ ︸
acid uptake
,(3)
dC
ds
= rI(s)︸ ︷︷ ︸
drug infusion
− m4C︸ ︷︷ ︸
drug decomposition
− d4CN2︸ ︷︷ ︸
drug-tumour
interaction removal
.(4)
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The conventions used here are that the subscript for each parameter corresponds to the relevant
equation; r represents growth rate; K represents carrying capacity; α represents population com-
petition strength; d represents rate of decrease due to interaction; m represents decrease through
system mechanisms. The parameters used in the model, their interpretation and potential val-
ues/range of values have been provided in Table 1.
Table 1. Table of parameters and estimated values
Parameter Units Description Value Source
r1 s
−1 normal cell growth rate O(10−6) [4, 10]
r2 s
−1 tumour cell growth rate O(10−6) [4, 10]
r3 M cm
3 s−1cells−1 H+ ion production rate 2.2× 10−17 [16]
d1 M
−1 s−1 fractional normal cell
kill by H+ ions
O(1) [10]
d2 M
−1 s−1 fractional tumor cell
kill by chemotherapy
9.3× 10−6 [5]
d4 cells
−1 s−1 fractional chemother-
apy removal by tumour
interaction
O(10−13)–O(10−12) estimated
m3 s
−1 H+ ion removal rate O(10−4) [10]
m4 s
−1 chemotherapy removal
rate
O(10−5) [4, 15]
K1 cells cm
−3 normal cell carrying
capacity
5× 107 [20]
K2 cells cm
−3 tumour cell carrying
capacity
5× 107 [20]
α1 none fractional normal cell
death due to tumour
cell
O(1) chosen freely
α2 none fractional tumour cell
death due to normal
cell
O(1) chosen freely
A question arises: What do we choose for f(N2) and rI(s)? In the model considered by
Gatenby and Gawlinski [10] and McGillen et al. [17] it was assumed that acid was produced
as a linear function of the tumour cell density, i.e. f(N2) = N2. In the model considered by
Holder et al. [14] a nonlinear acid production term was used as a result of the hypothesis that when
the tumour cell density was small, acid was produced at a rate proportional to the tumour cell den-
sity until a tumour cell saturation was reached at which point acid production would decrease to
zero. With this in mind, the function f(N2) = N2(1−N2/K2) was used. For simplicity we wish
to use the acid production term considered in [10] and [17], as such we have f(N2) = N2.
As for rI(s), we will choose appropriate functions to represent various treatment protocols.
Hence the most obvious, and perhaps most realistic, choice would be to chose a function that
is periodic, i.e. rI(s) = rI(s + P ), where P represents the length of the treatment cycle, or
period, as this would represent a treatment that occurs in repeated cycles such as taking pills or
an intravenous administration made in regularly scheduled doses. However, to enable a greater
potential for analysis we can choose rI(s) to be constant which would represent a constant infusion
of chemotherapy drug, i.e. via a device such as an intravenous pump. No matter the choice of rI(s)
we will naturally require it to meet the conditions that rI(s) ≥ 0 for all s ≥ 0 and that rI(s) is
bounded almost everywhere. These represent natural limitations on a treatment since a negative
infusion rate would represent removal of drug from the system and an unbounded infusion rate
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would represent an infinite amount of drug to be infused. In the case of administration by pills the
use of periodic Dirac delta functions (i.e. δ(s)) can be used to approximate this method of delivery:
Let P be the length of the treatment cycle and N being the total number of treatment cycles, then
(5) rI(s) = r4
N−1∑
n=0
δ(s− nP ).
In the case of intravenous infusion occurring in periodic cycles we can approximate this method of
delivery with periodic uses of a boxcar function: Let P denote the cycle period and s0 denote the
infusion time, then
(6) rI(s) = r4
N−1∑
n=0
[θ(s− nP )− θ(s− nP − s0)],
where r4 represents the constant rate of intravenous infusion and θ(s) is the Heaviside function.
Considering the function rI(s) with period P we let
r¯ =
1
P
∫ P
0
rI(s) ds
and then utilise the value r¯ to non-dimensionalise the equations given by (1)–(4). We remark that
this choice of parameter to non-dimensionalise the model enables us to effectively compare the
model when utilising different infusion functions. This is because under this non-dimensionalisation
the constant infusion rate is equal to the average infusion rate in the periodic case and this will im-
ply that the same amount of drug is infused per cycle no matter the infusion function used. Hence
we can compare the models that use the same non-dimensional parameter values.
Make the following substitutions
u1 =
N1
K1
, u2 =
N2
K2
, u3 =
m3
r3K2
H, u4 =
m4
r¯
C, t = r1s,
with
β2 =
r2
r1
, β3 =
m3
r1
, β4 =
m4
r1
, δ1 =
r3K2d1
r1m3
, δ2 =
d2r¯
r2m4
, δ4 =
d4K2
m4
and
i(t) =
rI(t/r1)
r¯
, ρ = r1P.
We then obtain the following system of non-dimensionalised equations
(7) u′ =

u′1
u′2
u′3
u′4
 =

u1(1− u1 − α1u2 − δ1u3)
β2u2(1− u2 − α2u1 − δ2u4)
β3(u2 − u3)
β4[i(t)− u4 − δ4u4u2]
 =: F(t,u),
where ( )′ denotes differentiation with respect to t. Note that
i¯ =
1
ρ
∫ ρ
0
i(t) dt = 1
and thus the average rate of infusion over each treatment cycle has been normalised to be equal to
one. Moreover, under this non-dimensionalisation, the functions (5) and (6) become
i(t) = ρ
N−1∑
n=0
δ(t− nρ)
and
(8) i(t) =
ρ
τ
N−1∑
n=0
[θ(t− nρ)− θ(t− nρ− τ)]; τ = r1s0,
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respectively.
A summary of potential non-dimensional parameter values/range of values and interpretation of
their meaning has been provided in Table 2. Note that the primary control parameter is δ2 since an
increase in the amount of drug infused will cause δ2 to increase.
Table 2. Table of non-dimensionalised parameters
Parameter Interpretation Value/Range
α1 fractional normal death due to tumour competition O(1)
α2 fractional tumour death due to normal competition O(1)
δ1 tumour aggressiveness O(1)
δ2 chemotherapy aggressiveness O(10−1)–O(1)
δ4 fractional removal due to interaction strength O(10−1)–O(1)
β2 relative tumour growth rate 1.0
β3 relative H+ ion production rate O(102)
β4 relative chemotherapy rate of increase O(10)
Note we define R+ = [0,∞) and the convention is used that if u,v ∈ Rn, then u ≤ (<)v
implies that uj ≤ (<)vj for all j ∈ {1, 2, 3, . . . , n}. Moreover, if c ∈ R, then u ≥ (>)c implies
that uj ≥ (>)c for all j ∈ {1, 2, 3, . . . , n}.
Theorem 2.1. Let i ∈ C(R+, [0, iM ]), where iM ∈ R and iM > 0. If u(0) ∈ R4+, then (7) has a
unique solution u that satisfies u(t) ∈ R4+ for all t ∈ R+.
Proof. We utilise Theorem A.7 that requires the existence of an invariant set, as given by Defini-
tion A.3. Clearly, F ∈ C(R+ × S,R4) and F′u ∈ C(R+ × S,R4
2
), where S is any compact set
in R4. This implies that F is Lipschitz continuous with respect to u in any compact set S ⊂ R4,
that is, there exists a constant L > 0 such that for any u1,u2 ∈ S ⊂ R4 and t ∈ R+, the following
inequality holds:
(9) ‖F(t,u1)− F(t,u2)‖ ≤ L‖u1 − u2‖.
The Cauchy–Schwarz inequality and (9) are now used to show that the one-sided Lipschitz con-
dition in Theorem A.7 is satisfied on any compact set S ⊂ R4. For any u1,u2 ∈ S ⊂ R4 and
t ∈ R+,
〈u1 − u2,F(t,u1)− F(t,u2)〉 ≤ ‖u1 − u2‖‖F(t,u1)− F(t,u2)‖ ≤ L‖u1 − u2‖2.
An invariant set, as given by Definition A.3, is now constructed in R4+. A set S ⊂ R4 will be
invariant with respect to (7) if
〈n(u),F(t,u)〉 ≤ 0 for t ∈ R+, u ∈ ∂S,
where n(u) is the outer normal to S at u. This invariance condition tells us that if u(0) ∈ S,
then the whole path of the solution u(t) will remain in S. Let S = E1 × E2 × E3 × E4, where
E1 = [0,max {1, u1(0)}], E2 = [0,max {1, u2(0)}], E3 = [0,max {1, u2(0), u3(0)}] and E4 =
[0,max {iM , u4(0)}]. Clearly, S ⊂ R4+, u(0) ∈ S and S is compact. Hence F will satisfy the
one-sided Lipschitz condition on S. The boundary of S (i.e ∂S) can be written as the union of
eight simple sets that have a simple outer normal. Let ∂Si1 = {u ∈ S : ui = inf Ei} and
∂Si2 = {u ∈ S : ui = supEi} for i = 1, 2, 3, 4, then ∂S =
⋃4
i=1 ∂Si1 ∪ ∂Si1. Furthermore,
each ∂Sij for i = 1, 2, 3, 4, j = 1, 2, has outer normal nij = (−1)jei, where ei for i = 1, 2, 3, 4
are the standard basis vectors in R4. Then, it is straightforward to show that
〈nij ,F(t,u)〉 = (−1)jFi(t,u) ≤ 0, for t ∈ R+, u ∈ ∂Sij , i = 1, 2, 3, 4, j = 1, 2.
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Hence the set S is invariant and F satisfies the one-sided Lipschitz condition on S. Therefore by
TheoremA.7, there exists a unique solution for all time to (7) with initial conditionu(0) ∈ S ⊂ R4+,
where the path of the solution remains in S. 
Note by a similar argument to the above proof, solutions u(t) of (7) are invariant on the sets
Γ1 = {0} × R3 and Γ2 = R × {0} × R2. Hence if there exists t1 ∈ R+ such that u1(t1) = 0,
then u1(t) = 0 for all t ∈ [t1,∞), similarly if there exists t2 ∈ R+ such that u2(t2) = 0, then
u2(t) = 0 for all t ∈ [t2,∞).
3. Constant infusion of chemotherapy drug
If we consider (7) with constant infusion (i.e. i(t) = 1), we obtain the system of equations
(10) u′ =

u′1
u′2
u′3
u′4
 =

u1(1− u1 − α1u2 − δ1u3)
β2u2(1− u2 − α2u1 − δ2u4)
β3(u2 − u3)
β4(1− u4 − δ4u4u2)
 .
3.1. Steady-state analysis. The natural method for analysis of a system of first-order nonlinear
autonomous ordinary differential equations (ODEs) is through the use of a steady-state (SS) anal-
ysis to determine the long-term behaviour of the system. A summary of the results of the SS
analysis and stability analysis for system (10) is presented below. For full details of the analysis
see Lemma C.1 in Appendix C.
System (10) has SS solutions:
SS1. u∗ = (0, 0, 0, 1);
SS2. u∗ = (1, 0, 0, 1);
SS3. u∗ = (0, uˆ2, uˆ2, [1 + δ4uˆ2]−1), where uˆ2 solves
δ4uˆ
2
2 + (1− δ4)uˆ2 + δ2 − 1 = 0;
SS4. u∗ = (1− (α1 + δ1)u˜2, u˜2, u˜2, [1 + δ4u˜2]−1), where u˜2 solves
δ4[1− α2(α1 + δ1)]u˜22 + [1− α2(α1 + δ1) + δ4(α2 − 1)]u˜2 + δ2 + α2 − 1 = 0.
However, note that the zero population SS (i.e. SS1) is unconditionally unstable and as a result
the solution should always tend towards containing a population of either normal-tissue or tumour-
tissue. We see that the tumour free SS (i.e. SS2) is stable provided α2 + δ2 > 1. Therefore
assuming there is a tumour population, we at the least require this condition to remove the tumour
from the system. This condition corresponds to a sufficiently strong treatment in combination with
a sufficiently strong population competition provided by the normal-tissue. This state represents
the desired state of existence for the system from the point of view of the patient. Hence it is an
aim to discover how the system can be altered to make SS2 the most likely long term solution.
It can be seen from Lemma C.1(iii) that the normal-tissue free SS (i.e. SS3) is stable provided
certain parameter conditions are met: these being if
δ2 <
(α1 + δ1 + δ4)(α1 + δ1 − 1)
(α1 + δ1)2
,
or if
(α1 + δ1 + δ4)(α1 + δ1 − 1)
(α1 + δ1)2
≤ δ2 < (1 + δ4)
2
4δ4
and
1
δ4
<
α1 + δ1 − 2
α1 + δ1
.
This state corresponds to an invasive tumour population in which all normal-tissue in the region
is destroyed and replaced by the advancing tumour. Note that from the stability conditions, for the
normal-tissue free population to be stable it is a necessary condition that α1+δ1 > 1, otherwise the
SSwill be unconditionally unstable. This means that the tumour needs to provide sufficiently strong
population competition and destructive influence of the acid to potentially be stable. Furthermore,
the destructive influence of the treatment (δ2) needs to be sufficiently small or, alternatively, the
removal of chemotherapy drug from interaction with tumour cells (δ4) needs to be sufficiently large
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to ensure that the normal-tissue free state is stable. We remark that if δ2 > (1 + δ4)2/4δ4, then the
normal-tissue free state does not exist (i.e. uˆ2 /∈ R). Hence this condition represents a scenario
in which the tumour will be completely removed from the system by the treatment alone. As δ2
directly relates to the strength of the treatment dose, to obtain a value of δ2 that will ensure the
removal of the tumour by treatment alone may present safety and health concerns for the patient
[6, 19]. However, from the stability conditions, should the tumour-tissue population competition,
the destructive influence of the acid or the removal of drug by interaction with the tumour be
decreased, then this could enable the tumour to be removed without using a dangerous treatment
dose. As noted in [7, 12] the use of an acid buffer to decrease the acidity could be a potential method
to increase the efficacy of the treatment without further increasing doses of strong cytotoxic drugs.
The normal-tissue free state can be stable when the tumour-tissue free state is either unstable
or stable. In the case the normal-tissue free state is stable when the tumour-tissue free state is
unstable, the long term behaviour would be for the tumour to establish a fixed population that
cannot be eradicated by the current treatment protocol. This would suggest that the normal-tissue
and chemotherapy treatment would be weak in relation to the tumour-tissue and would potentially
correspond to a very aggressive tumour. In the case that both the tumour-tissue free state and the
normal-tissue free state are stable, the question of whether the treatment will be effective or the
tumour population will successfully invade is dependent on the initial conditions. Therefore the
suggestion is that the effectiveness of the treatment will be determined by the size of the initial
tumour population. This is consistent with the decreased probability of a cure associated with
larger and more established tumour cell populations [19].
The coexistence of tumour- and normal-tissue SS (i.e. SS4) is stable and exists for a compli-
cated, yet still calculable, set of parameter conditions given in Lemma C.1(iv). These parameter
conditions suggest that in order for the coexistence state to exist, the system requires unaggres-
sive tumour- and normal-tissue in combination with a weak treatment response. That is, there
needs to be very low population competition, tumour aggressiveness and destructive influence of
the chemotherapy treatment. As in [10], this suggests that the SS would represent a benign state
of existence. The coexistence SS can potentially change to either the tumour-tissue free SS or
the normal-tissue free SS provided a sufficient change occurs in the parameters. Should the tu-
mour aggressiveness or the tumour-tissue population competition increase, then the tumour would
transition to the invasive state, where the normal-tissue free state is stable. Similarly, should the
normal-tissue population competition or the destructive influence of the treatment increase, then
the tumour will be eradicated from the system.
3.2. A reduced model with constant infusion. If we consider the situation originally examined
in [1] we have the system of equations
(11) x′ =
[
x′1
x′2
]
=
[
β2x1(1− x1 − δ2x2)
β4(1− x2 − δ4x1x2)
]
.
If α2 = 0 in (10), then the reduced system (11) provides the governing dynamics for the tumour-
tissue density and cytotoxic drug concentration. Analysing this systemwe can obtain the conditions
under which it is sufficient to obtain tumour clearance from the system by chemotherapy drug
without the assistance of population competition. The results for this model are considered in [1],
however we provide them here in the current parameters for the convenience of the reader and easy
reference for further results in this article. As in [1], see that this system has the SS solutions:
RS1. x∗ = (0, 1);
RS2. x∗ =
(
uˆ2, [1 + δ4uˆ2]
−1), where δ4uˆ22 + (1− δ4)uˆ2 + δ2 − 1 = 0.
Note that these are the same values for the tumour density and drug concentration obtained for SS2
and SS3, respectively. Hence we have that this quadratic equation has the solutions
uˆ2± =
δ4 − 1±
√
(1− δ4)2 + 4δ4(1− δ2)
2δ4
,
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where uˆ2± ∈ R if and only if δ2 ≤ (1 + δ4)2/4δ4.
As is shown by Byrne [1], RS1 is stable for δ2 > 1, and RS2 is stable if
δ2 < 1, or if 1 ≤ δ2 < (1 + δ4)
2
4δ4
and δ4 > 1.
Note that the SS x∗ = (uˆ2−, 1/(1 + δ4uˆ2−)) is unconditionally unstable. In the case 1 < δ2 <
(1 + δ4)
2/4δ4 and δ4 > 1 this SS is positive and represents a point on which the separatrix lies.
Furthermore, it can be shown that if δ2 ≥ 1 and δ4 < 1, or if δ2 > (1 + δ4)2/4δ4, that
the long term behaviour of the model will be for the tumour to be eradicated from the system,
since not only is RS2 unstable but also biologically meaningless. Moreover, note that under this
parameter condition in the case of the full system (10) we similarly get that the tumour-tissue free
SS (i.e. SS2) is the only stable solution and as a result the tumour will be eradicated from the
system. We remark that in the case of the parameter condition δ2 > (1 + δ4)2/4δ4, RS2 does
not exist as uˆ2 /∈ R. This would suggest that if this condition is satisfied, then the chemotherapy
treatment alone will be sufficient to eradicate the tumour without the assistance of the normal cell
population to weaken the tumour cells through competition. We can see that under these conditions
that the tumour will always be eradicated since should the population of normal cells be zero, the
governing dynamics of the system will reduce to that given by (11). Therefore this indicates that
there is a sufficient scenario under which a tumour will be cleared from the system regardless of the
interactions between normal and tumour-tissue. Whilst this observation is an ideal aim to achieve, it
is not always feasible or possible due to the fact that this may require doses which would potentially
kill the host or require the interaction between the treatment and tumour-tissue to be sufficiently
weighted in favour of the treatment.
In the case δ2 < 1we have a situation in which the tumour free solution is unstable and hence this
would suggest that the tumour is not able to be removed from the system by chemotherapy. However
if we are considering the system given by (10), provided a condition on population competition is
satisfied (i.e. α2 + δ2 > 1), the tumour free solution will become stable. Furthermore, should
tumour aggressiveness and competition be sufficiently small (see Lemma C.1(i)) we will have that
the normal-tissue free SS will become unstable. Therefore under these conditions we will have that
the tumour will be eradicated from the system by the combined strength of population competition
and chemotherapy treatment.
4. Periodic infusion of chemotherapy drug
In Section 2 we stated that a more realistic function for the infusion of drug is a periodic function
such as considered in [4, 5]. Hence assume that i(t+ ρ) = i(t) ≥ 0 for all t ∈ R+. Some prelimi-
nary numerical simulations of (7) were run, with i(t) given by (8), using the ode15s command in
MATLAB with parameter values consistent with Table 2. The values ρ = 2.8 (P approximately 1
week), τ = 1.2 (s0 approximately 3 days) and total time T = 40 (approximately 3-4 months) were
used with initial values u(0) = (0.9, 0.1, 0.1, 0). In these simulations three different behaviours
occurred: the eradication of the tumour from the system; the “invasion” of the tumour and subse-
quent destruction of the normal-tissue; the coexistence of the tumour and normal-tissue. Examples
of these behaviours are displayed in Figures 1–3, respectively.
Notice in each of these figures that the solutions evolve towards stable ρ-periodic solutions (i.e.
u(t) = u(t+ ρ)). Therefore to analyse this model we look for time-periodic solutions to (7) with
period ρ (i.e. u(t + ρ) = u(t) for all t ∈ R+) and analyse the stability of these solutions to
determine the long term behaviour of the system. This is analogous to a steady-state analysis or
limit-cycle analysis for an autonomous system of equations.
A reduced version of system (7) is considered first that corresponds to when the solution for
u1 ≡ 0. The system considered will be analogous to the reduced system considered in Section 3.2.
Moreover, the reduced system corresponds to that originally proposed in [1]. Byrne [1] however
did not analyse the system in this form, but rather made the simplifying assumption that the drug
concentration was equivalent to the infusion function which was given by (8). This reduced the
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Figure 1. Simulation of (7) for α1 = 1, α2 = 0.5, β2 = 1, β3 = 70, β4 = 20,
δ1 = 12.5, δ2 = 1.1, δ4 = 0.6
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Figure 2. Simulation of (7) for α1 = 1, α2 = 0.5, β2 = 1, β3 = 70, β4 = 20,
δ1 = 12.5, δ2 = 0.1, δ4 = 1
system to a single explicitly solvable Bernoulli equation. Here we present a more thorough analysis
of this model for general ρ-periodic functions i ∈ C(R+).
4.1. Existence, uniqueness and stability of the periodic solution of a reduced system. Con-
sider the system
(12) x′ =
[
x′1
x′2
]
=
[
β2x1(1− x1 − δ2x2)
β4[i(t)− x2 − δ4x1x2]
]
=: G(t,x).
The results of Lemma B.3 show that periodic solutions can exist for system (12) only if δ2 < 1,
or only if 1 ≤ δ2 < (1 + δ4)2/4δ4 and δ4 > 1. Hence this guides the region of parameter values
for which we look for ρ-periodic solutions to exist for (12).
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Figure 3. Simulation of (7) for α1 = 0.25, α2 = 0.25, β2 = 1, β3 = 70,
β4 = 20, δ1 = 0.25, δ2 = 0.25, δ4 = 1
4.1.1. Existence. Suppose that δ2 < 1 and consider the systems
(13)
¯
x′ =
[
¯
x′1
¯
x′2
]
=
[
β2
¯
x1(1−
¯
x1 − δ2
¯
x2)
β4[i(t)−
¯
x2]
]
=:
¯
G(t,
¯
x)
and
(14) x¯′ =
[
x¯′1
x¯′2
]
=
[
β2x¯1(1− x¯1)
β4[i(t)− x¯2 − δ4x¯1x¯2]
]
=: G¯(t, x¯).
Consider (12), (13) and (14) with a given initial condition η = (η1, η2) ∈ R2+. Following
the proof of the existence and uniqueness theorem for the full system (7), it can be shown that a
unique solution exists for (12), (13) and (14) that are invariant on the region [0,max{1, η1}] ×
[0,max{iM , η2}]. Thus if x(0),
¯
x(0), x¯(0) ∈ [0, 1]× R+, then x(t),
¯
x(t), x¯(t) ∈ [0, 1]× R+ for
all t ∈ R+.
Note that the solutions for (13) and (14) are given by
¯
x(t) =
[
v(t;β2(1− δ2
¯
x2), β2)
w(t;β4i, β4)
]
and
x¯(t) =
[
v(t;β2, β2)
w(t;β4i, β4(1 + δ4x¯1))
]
,
where w and v are as in Lemmata B.1 and B.2, respectively.
Let D = [0, 1] × R+ and M = diag(1,−1) = M−1; assume that x(0),
¯
x(0), x¯(0) ∈ D and
M
¯
x(0) ≤Mx(0) ≤M x¯(0). We claim that
(15) M
¯
x(t) ≤Mx(t) ≤M x¯(t) for all t ∈ R+.
It is clear that G′x, ¯
G′x, G¯
′
x ∈ C(R+ × R2,R2
2
), hence G, G¯,
¯
G each satisfy a local Lipschitz
condition on any Ω ⊂ R+ × R4. It can easily be seen thatM
¯
G(t,η) ≤ MG(t,η) ≤ MG¯(t,η)
for all (t,η) ∈ R+ × D. Letting E = [0, 1] × (−∞, 0], we see that the Jacobian matrices
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[MG(t,Mη)]′η and [MG¯(t,Mη)]′η are essentially positive (see Remark A.2) on R+×E, mean-
ingMG(t,Mη) andMG¯(t,Mη) are quasimonotone increasing (see Definition A.1) onR+×E.
Hence by Corollary A.9 the claim is proved true.
S
•
η = u(0;η)
•
ϕ(η) = u(ρ;η)
u(t;η)
Figure 4. Diagram showing solutions u initially in S ⊂ R3 will be in S at time ρ
After having established the time-dependent bounds (15) on the solution of (12), we are ready
to prove the actual existence of a ρ-periodic solution to (12). Define the rectangle
R = {η ∈ R2+ : M¯x(0) ≤Mη ≤M x¯(0)}.
Let η = x(0) ∈ R. Denote by x(·;η) the solution of (12) with initial condition η ∈ R. Define a
map ϕ : R→ R2+ by
ϕ(η) := x(ρ;η)
for every η ∈ R. We wish to apply Brouwer’s Fixed Point Theorem to ensure the existence of a
fixed point of ϕ, i.e. we want to show that there is some initial condition η0 ∈ R for which
ϕ(η0) = x(ρ;η0) = η0.
For this particular initial condition, x(ρ) = x(0). This idea is illustrated in Figure 4 for u ∈ R3.
Then a result from [8] will enable us to conclude that x(t) = x(t+ ρ) for all t ∈ R+.
It is clear that ϕ is continuous on R. Using Lemmata B.1 and B.2, if we pick
¯
x(0) =
[
v(0;β2(1− δ2
¯
x2), β2)
w(0;β4i, β4)
]
=
 1−e− ∫ ρ0 g(s′) ds′β2 ∫ ρ0 e− ∫ ρs g(s′) ds′ ds
β4
eβ4ρ−1
∫ ρ
0 e
β4si(s) ds
 ,
where g(s) = β2[1 − δ2
¯
x2(s)], then
¯
x(t + ρ) =
¯
x(t) > 0 for all t ≥ 0. This is true provided∫ ρ
0 g(s) ds > 0. From Lemma B.1, we see that∫ ρ
0 ¯
x2(s) ds =
∫ ρ
0
i(s) ds = ρ.
Recalling that δ2 < 1, we obtain
δ2
∫ ρ
0 ¯
x2(s) ds < ρ, or
∫ ρ
0
g(s) ds =
∫ ρ
0
β2[1− δ2
¯
x2(s)] ds > 0.
Similarly, from Lemmata B.1 and B.2, if we choose
x¯(0) =
[
v(0;β2, β2)
w(0;β4i, β4(1 + δ4x¯1))
]
=
[
1
β4
e(1+δ4)β4ρ−1
∫ ρ
0 e
(1+δ4)β4si(s) ds
]
,
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then x¯(t+ρ) = x¯(t) > 0 for all t ≥ 0. Furthermore, as β4 < β4[1+δ4x¯1(t)] and β2[1−δ2
¯
x2(t)] <
β2 for t ∈ R+ we have from Lemmata B.1 and B.2 thatM
¯
x(t) ≤M x¯(t) for all t ∈ R+. With the
above choices for
¯
x(0) and x¯(0) we have that R ⊂ int(R2+) and
M
¯
x(0) = M
¯
x(ρ) ≤Mx(ρ;η) ≤M x¯(ρ) = M x¯(0),
that is, ϕ(η) ∈ R, which implies that ϕ(R) ⊂ R. By Brouwer’s Fixed Point Theorem there is
some initial condition η0 ∈ R ⊂ int(R2+) for which
ϕ(η0) = x(ρ;η0) = η0.
For this particular initial condition, x(ρ) = x(0). Then from [8, Lemma 2.2.1] we have
x(t+ ρ) = x(t) > 0 for all t ∈ R+,
thus showing the existence of a strictly positive ρ-periodic solution to (12).
Now we prove the uniqueness of the solution constructed above.
4.1.2. Uniqueness. Note that if u(t) ≥ 0 and v(t) ≥ 0 are solutions to (12) and u(t0) = v(t0) at
some t0 ∈ R+, then u(t) = v(t) for all t ∈ R+ by uniqueness.
Now, let u(t),v(t) > 0 be ρ-periodic solutions of (12). It will be shown that u1(t) = v1(t) for
all t ∈ R+ if and only if u2(t) = v2(t) for all t ∈ R+. If u1(t) = v1(t) for all t ∈ R+, then from
(12) and periodicity it can be seen that
0 =
∫ ρ
0
[u1(s)− v1(s)] ds+ δ2
∫ ρ
0
[u2(s)− v2(s)] ds = δ2
∫ ρ
0
[u2(s)− v2(s)] ds.
Hence by the Mean Value Theorem there exists t0 ∈ (0, ρ) such that u2(t0) − v2(t0) = 0 (i.e.
u2(t0) = v2(t0)) and since u1(t) = v1(t) for all t ∈ R+ it follows that u(t0) = v(t0) which
implies u(t) = v(t) for all t ∈ R+, i.e. u2(t) = v2(t) for all t ∈ R+. It can be shown similarly
that if u2(t) = v2(t) for all t ∈ R+, then u1(t) = v1(t) for all t ∈ R+.
Let u(t) ≥ 0 and v(t) ≥ 0 be distinct ρ-periodic solutions of (12). It will now be shown that
u1(t) ≤ (≥)v1(t) for all t ∈ R+ and there exists t1 ∈ [0, ρ) such that u1(t1) < (>)v1(t1). Since
u(t) and v(t) are ρ-periodic it is sufficient to show u1(t) ≤ (≥)v1(t) for all t ∈ [0, ρ).
Assume that there exists t2 ∈ [0, ρ) such that u1(t2) = v1(t2), then as u(t) and v(t) are distinct
we must have u2(t2) 6= v2(t2). Assume u2(t2) > (<)u2(t2), then lettingM = diag(1,−1) we
have Mv(t2) ≥ (≤)Mu(t2), which shows by Theorem A.8 that Mv(t) ≥ (≤)Mu(t) for all
t ∈ [t2,∞) (i.e. u1(t) ≤ (≥)v1(t) and u2(t) ≥ (≤)v2(t) for all t ∈ [t2,∞)), and by periodicity of
u(t) and v(t) this must hold for all t ∈ R+. Furthermore since u1(t) = v1(t) for t ∈ R+ implies
u(t) and v(t) are not distinct there must exist t1 ∈ [0, ρ) such that u1(t1) < (>)v1(t1). Now if
u1(t) 6= v1(t) for any t ∈ [0, ρ), then as a consequence of the continuity of u(t) and v(t) and the
Intermediate Value Theorem u1(t) < (>)v1(t) for all t ∈ R+.
Assume that u(t) > 0 and v(t) > 0 are distinct ρ-periodic solutions to (12), then as shown
previously this implies without loss of generality that u1(t) ≤ v1(t) for all t ∈ R+ and there exists
t1 ∈ [0, ρ) such that u1(t1) < v1(t1). From Lemma B.3, u1(t) is given by the implicit form
(16) u1(t) =
δ4 − 1 +
√
(1 + δ4)2 + 4δ4[f(t)− δ2i(t)]
2δ4
, f(t) =
d
dt
V (u(t))
and v1(t) is given by the implicit form
(17) v1(t) =
δ4 − 1 +
√
(1 + δ4)2 + 4δ4[g(t)− δ2i(t)]
2δ4
, g(t) =
d
dt
V (v(t)),
noting that f and g must be continuous by the continuity of u > 0 and v > 0. Since u1(t) ≤ v1(t)
for all t ∈ R+ and there exists t1 ∈ [0, ρ) such that u1(t1) < v1(t1), then (16) and (17) implies
f(t) ≤ g(t) for all t ∈ R+ and f(t1) < g(t1). By continuity this implies∫ ρ
0
[g(s)− f(s)] ds > 0.
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However by the periodicity of u(t) and v(t)∫ ρ
0
[g(s)− f(s)] ds = 0,
which is a contradiction, hence u1(t) and v1(t) cannot be distinct (i.e. u1(t) = v1(t)) which
implies that u2(t) and v2(t) are not distinct (i.e. u2(t) = v2(t)).
We have therefore proved the following theorem:
Theorem 4.1. Suppose that 0 < δ2 < 1. Then (12) has a unique solution x that satisfies
x(t+ ρ) = x(t) > 0 for all t ∈ R+.
4.1.3. Stability. Here we prove the stability of the strictly positive ρ-periodic solution of (12) by
utilising [8, Theorem 4.2.1]. We summarise the required results of [8] below.
Let
(18) u′ = F(t,u),
where F ∈ C(R × X,Rn), F′u ∈ C(R × X,Rn
2
), X is an open connected subset of Rn and
F(t, ·) = F(t+ ρ, ·). Let u : R→ X be a non-constant ρ-periodic solution to (18). Then making
the coordinate transformation z = u− p(t) we have
z′ = F(t, z + p(t))− F(t,p(t)) = F′u(t,p(t))z + o(|z|).
Hence the linearisation of (18) at p(t) is given by
(19) y′ = F′u(t,p(t))y.
If Φ(t) represents the fundamental matrix solution of (19), then the characteristic multipliers of
(19) are given by the eigenvalues of Φ(ρ).
From [8, Theorem 4.2.1], if all the characteristic multipliers of system (19) are in modulus less
than 1 (i.e. the spectral radius of Φ(ρ) is less than 1), then p is a uniformly asymptotically stable
solution of (18); if (19) has at least one characteristic multiplier with modulus greater than 1 (i.e.
the spectral radius of Φ(ρ) is greater than 1), then p is unstable.
Consider (12), which when linearised about a strictly positive ρ-periodic solution x produces
the system
(20)
dz
dt
=
[
β2[1− 2x1(t)− δ2x2(t)] −β2δ2x1(t)
−β4δ4x2(t) −β4[1 + δ4x1(t)]
]
z =: A(t)z.
The fundamental matrix Φ(t) of this system satisfies
dΦ
dt
= A(t)Φ, Φ(0) = I.
Let P be a 2 × 2 invertible, differentiable matrix function such that P (t + ρ) = P (t) for all
t ∈ R+. If we let y(t) = P (t)z(t), then y satisfies
(21)
dy
dt
= [P ′(t) + P (t)A(t)]P−1(t)y =: B(t)y.
The fundamental matrix Ψ(t) of this system satisfies
dΨ
dt
= B(t)Ψ, Ψ(0) = I,
where I is the identity matrix. It can easily be shown that P (t)Φ(t)P−1(0) is a fundamental
matrix solution of (21), that is, Ψ(t) = P (t)Φ(t)P−1(0). Since P (t + ρ) = P (t), it is clear that
Ψ(ρ) = P (ρ)Φ(ρ)P−1(ρ) (i.e. Ψ(ρ) is similar to Φ(ρ)), hence Ψ(ρ) and Φ(ρ) have the same
eigenvalues. This demonstrates the requirement for P to be ρ-periodic.
We let
P (t) =
[
p11(t) 0
0 p22(t)
]
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for some ρ-periodic functions p11 and p22 to be determined, which implies
B =
[
p′11
p11
+ a11
p11a12
p22
p22a21
p11
p′22
p22
+ a22
]
.
We want p11(t)p22(t) < 0 so that b12(t) > 0 and b21(t) > 0 (i.e. B is essentially positive). Since
B(t) is essentially positive for all t ∈ R+, the same argument as that used in [8, p. 190] shows that
each entry of Ψ(t) is positive for t ∈ [0, ρ]. In particular, each entry of Ψ(ρ) is positive. Let λ1, λ2
denote the eigenvalues of Ψ(ρ), that is, the characteristic multipliers of (21).
By Perron’s Theorem, Ψ(ρ) has a unique largest positive eigenvalue λ2, say, with a correspond-
ing eigenvector v =
[
v1 v2
]T having strictly positive components such that |λ1| < λ2. Hence
for x to be stable, we need to show that λ2 < 1.
Let y(t) = Ψ(t)v, where v is such that Ψ(ρ)v = λ2v. Then y satisfies dy/dt = B(t)y. If
y(t) =
[
y1(t) y2(t)
]T, it follows that y(t) > 0 for all t ∈ [0, ρ]. Suppose that for the moment
that we can find a ρ-periodic function ξ(t) =
[
ξ1(t) ξ2(t)
]T such that
〈ξ(0),y(0)〉 > 0 and
∫ ρ
0
d
dt
〈ξ(t),y(t)〉 dt < 0.
Then 〈ξ(ρ),y(ρ)〉 < 〈ξ(0),y(0)〉; however y(ρ) = Ψ(ρ)v = λ2v, so that 〈ξ(0), λ2v〉 <
〈ξ(0),v〉 and this would show that λ2 < 1. We now proceed to find the desired function ξ(t).
We have
〈ξ,y〉′ = 〈ξ′,y〉+ 〈ξ,y′〉 = 〈ξ′,y〉+ 〈ξ, By〉
=
〈
ξ′,y
〉
+
〈
BTξ,y
〉
=
〈
ξ′ +BTξ,y
〉
=
[
ξ′1 +
(
p′11
p11
+ a11
)
ξ1 +
p22a21
p11
ξ2
]
y1
+
[
ξ′2 +
p11a12
p22
ξ1 +
(
p′22
p22
+ a22
)
ξ2
]
y2.
Take
p11(t) =
1
x1(t)
, p22(t) = −β2δ2, ξ1(t) = β4[1 + δ4x1(t)], ξ2(t) = 1
for example, which are all ρ-periodic and p11(t)p22(t) < 0 for all t ∈ R+. We also note that
〈ξ(0),y(0)〉 > 0. This makes the coefficient of y2 equal to zero, so that
〈ξ,y〉′ = β2β4x1(δ4 − 1− 2δ4x1)y1
after some algebra.
Suppose that δ2 < 1. Then from Lemma B.3
x1(t) =
(δ4 − 1) +
√
(δ4 − 1)2 + 4δ4[1− δ2i(t) + h(t)]
2δ4
, where h(t) =
d
dt
V (x(t)),
which implies that
δ4 − 1− 2δ4x1(t) = −
√
(1− δ4)2 + 4δ4[1− δ2i(t) + h(t)] ≤ 0.
Moreover, from the periodicity of x it can be seen that (1/ρ)
∫ ρ
0 [δ2i(s)− h(s)] ds = δ2. Thus
from the Mean Value Theorem there exists t∗ ∈ (0, ρ) such that
(1− δ4)2 + 4δ4[1− δ2i(t∗) + h(t∗)] = (1− δ4)2 + 4δ4(1− δ2).
Since δ2 < 1, it follows that (1− δ4)2 + 4δ4(1− δ2) > 0 and then by continuity, there exists  > 0
such that
(1− δ4)2 + 4δ4[1− δ2i(t) + h(t)] > 0 for all t ∈ (t∗ − , t∗ + ).
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This yields, by the strict positivity of x and y,∫ t∗+
t∗−
x1(t)[δ4 − 1− 2δ4x1(t)]y1(t) dt < 0.
Thus, ∫ ρ
0
d
dt
〈ξ(t),y(t)〉 dt =
∫ ρ
0
β2β4x1(t)[δ4 − 1− 2δ4x1(t)]y1(t) dt
=
∫ t∗−
0
β2β4x1(t)[δ4 − 1− 2δ4x1(t)]y1(t) dt
+
∫ t∗+
t∗−
β2β4x1(t)[δ4 − 1− 2δ4x1(t)]y1(t) dt
+
∫ ρ
t∗+
β2β4x1(t)[δ4 − 1− 2δ4x1(t)]y1(t) dt
< 0.
The above argument then shows that if δ2 < 1 and a strictly positive ρ-periodic solution exists to
(12), then |λ1| < λ2 < 1 (i.e. x is asymptotically stable). Therefore the unique ρ-periodic solution
of (12) found in Section 4.1.1 is asymptotically stable.
Remark 4.2. As a result of Lemma B.3 any strictly positive ρ-periodic solution x to (12) must
satisfy the implicit form
(22) x1(t) =
(δ4 − 1)±
√
(δ4 + 1)2 − 4δ4[δ2i(t)− h(t)]
2δ4
, where h(t) =
d
dt
V (x(t)).
By a similar argument to the above it can be concluded that if δ2 < 1 or if 1 ≤ δ2 < (1 + δ4)2/4δ4
and δ4 > 1 and a strictly positive ρ-periodic solution exists for (12) that satisfies the “plus” case
of (22), then |λ1| < λ2 < 1 (i.e. x is asymptotically stable). Similarly, it can be concluded that
if a strictly positive ρ-periodic solution exists for (12) that satisfies the “minus” case of (22), then
λ2 > 1 (i.e. x is unstable).
4.2. Existence of co-existence periodic solution. The existence of a strictly positive ρ-periodic
solution to the full system (7) will be shown in this section.
Note that (7) is invariant on R4+. Consider the systems
(23)
¯
u′ =
¯
u′1
¯
u′2
¯
u′3
¯
u′4
 =
¯
u1(1−
¯
u1 − α1
¯
u2 − δ1
¯
u3)
β2
¯
u2(1−
¯
u2 − δ2
¯
u4)
β3(
¯
u2 −
¯
u3)
β4[i(t)−
¯
u4 − δ4
¯
u4
¯
u2]
 =: ¯F(t, ¯u),
and
(24) u¯′ =

u¯′1
u¯′2
u¯′3
u¯′4
 =

u¯1(1− u¯1 − α1u¯2)
β2u¯2(1− u¯2 − α2u¯1 − δ2u¯4)
β3(u¯2 − u¯3)
β4[i(t)− u¯4]
 =: F¯(t, u¯).
Similarly to (7) the solutions to (23) and (24) can be shown to be unique and invariant on R4+.
We now wish to establish the existence of strictly positive ρ-periodic solutions to (23) and (24).
First consider (23) and let
¯
u(t) denote a solution, where
¯
u(0) ∈ R4+. From the analysis of the
normal-tissue free system, if δ2 < 1 there is a unique strictly positive ρ-periodic solution to
¯
u′2 =
¯
F2(t,
¯
u) and
¯
u′4 = ¯
F4(t,
¯
u). Then from Lemma B.1 there exists a unique ρ-periodic solution to
¯
u′3 = ¯
F3(t,
¯
u), where
¯
u3(t) = w(t;β3
¯
u2, β3) with initial condition given by (31). Using these
ρ-periodic solutions and Lemma B.2 if
∫ ρ
0 [1− α1¯u2(s)− δ1¯u3(s)] ds > 0, there exists a unique
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strictly positive ρ-periodic solution to
¯
u′1 = ¯
F1(t,
¯
u), where
¯
u1(t) = v(t; 1−α1
¯
u2− δ1
¯
u3, 1) with
initial condition given by (34). Consider∫ ρ
0
[1− α1
¯
u2(s)− δ1
¯
u3(s)] ds =
∫ ρ
0
[1− (α1 + δ1)
¯
u2(s)] ds ≥ 1− (α1 + δ1)uˆ2+
from Lemmata B.1 and B.3. Hence if δ2 < 1 and 1− (α1 + δ1)uˆ2+ > 0, then there exists a unique
strictly positive ρ-periodic solution to (23).
Now consider system (24) and let u¯(t) denote a solution, where u¯(0) ∈ R4+. From the analysis
of the normal-tissue free problem it is known that there exists a unique strictly positive ρ-periodic
solution to u¯′4 = F¯4(t, u¯). Then from [13, Prop. 36.1 and 36.3] there exists a unique strictly
positive ρ-periodic solution to u¯′1 = F¯1(t, u¯) and u¯′2 = F¯2(t, u¯) if
1 < (>)α1
1
ρ
∫ ρ
0
[1− δ2u¯4(s)] ds = α1(1− δ2)
and
1
ρ
∫ ρ
0
[1− δ2u¯4(s)] ds = 1− δ2 < (>)α2.
Noting u¯2(t) > 0 for all t ∈ R+, we have from Lemma B.1 that u¯′3 = F¯3(t, u¯) has a unique strictly
positive ρ-periodic solution given by u¯3(t) = w(t;β3u¯2, β3) with initial condition given by (31).
Assume that the parameter conditions
(25) δ2 < 1, 1− (α1 + δ1)uˆ2+ > 0, 1 < (>)α1(1− δ2) and 1− δ2 < (>)α2
are satisfied, then there exists unique strictly positive ρ-periodic solutions to (23) and (24) denoted
by
¯
u(t) and u¯(t), respectively. Letting M = diag(1,−1,−1, 1) = M−1, we wish to show that
M
¯
u(t) ≤M u¯(t) for all t ∈ R+. It was shown in the analysis of the normal-tissue free ρ-periodic
solution that
¯
u4(t) ≤ u¯4(t) for all t ∈ R+. Consider the ρ-periodic solutions
¯
u2(t) and u¯2(t) that
satisfy
¯
u′2 = β2¯
u2[1−
¯
u4(t)−
¯
u2] and u¯′2 = β2u¯2[1− α2u¯1(t)− δ2u¯4(t)− u¯2].
Note that 1 − δ2u¯4(t) − α2u¯1(t) < 1 − δ2
¯
u4(t) for all t ∈ R+ and by Lemma B.2 it must hold
that
∫ ρ
0 [1− δ2u¯4(s)− α2u¯1(s)] ds > 0 and moreover, ¯u2(t) ≥ u¯2(t) for all t ∈ R+. Consideringthe evolution of
¯
u3(t) − u¯3(t) it then follows directly from Lemma B.1 that
¯
u3(t) ≥ u¯3(t) for all
t ∈ R+.
Consider
¯
u1(t) and u¯1(t) which satisfy
¯
u′1 = ¯
u1[1− α1
¯
u2(t)− δ1
¯
u3(t)−
¯
u1] and u¯′1 = u¯1[1− α1u¯2(t)− u¯1].
Note that
∫ ρ
0 [1− α1¯u2(s)− δ1¯u3(s)] ds > 0 and that 1 − α1¯u2(t) − δ1¯u3(t) < 1 − α1u¯2(t) forall t ∈ R+. Then from Lemma B.2,
¯
u1(t) ≤ u¯1(t) for all t ∈ R+. Hence it has been shown that
M
¯
u(t) ≤M u¯(t) for all t ∈ R+.
Assume that u(0),
¯
u(0), u¯(0) ∈ R+ andM
¯
u(0) ≤Mu(0) ≤M u¯(0). We claim that
(26) M
¯
u(t) ≤Mu(t) ≤M u¯(t) for all t ∈ R+.
It is clear that F′u, ¯
F′u, F¯
′
u ∈ C(R+ × R4,R4
2
), hence F, F¯,
¯
F each satisfy a local Lipschitz
condition on any D ⊂ R+ × R4. It can easily be seen thatM
¯
F(t,η) ≤ MF(t,η) ≤ M F¯(t,η)
for all (t,η) ∈ R1+4+ . Letting E = R+ × (−∞, 0]2 × R+, we can see that the Jacobian matrices
[MF(t,Mη)]′η and [M F¯(t,Mη)]′η are essentially positive onR+×E, meaningMF(t,Mη) and
M F¯(t,Mη) are quasimonotone increasing onR+×E. Hence by Corollary A.9 the claim is proved
true.
Theorem 4.3. If (25) is satisfied, then there exists a strictly positive ρ-periodic solution to (7).
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Proof. Under the given parameter restrictions there exist strictly positive ρ-periodic solutions to
(23) and (24). Let
¯
u(t) and u¯(t) denote the strictly positive ρ-periodic solutions for systems (23)
and (24), respectively. Note that it was shownM
¯
u(t) ≤M u¯(t) for all t ∈ R+. Construct the box
R = {η ∈ R4+ : M¯u(0) ≤Mη ≤M u¯(0)} ⊂ int(R
4
+)
and define the solution of (7) with initial condition η ∈ R as u(t;η), i.e. u(0;η) = η. Define the
map ϕ : R→ R4+ by
ϕ(η) = u(ρ,η) for η ∈ R.
Note from continuous dependence on initial conditions that ϕ is clearly continuous. If η ∈ R, then
from (26) it is clear that
(27) M
¯
u(t) ≤Mu(t;η) ≤M u¯(t) for all t ∈ R+.
Then from the periodicity of
¯
u(t) and u¯(t) it follows that
M
¯
u(0) = M
¯
u(ρ) ≤Mu(ρ;η) ≤M u¯(ρ) = M u¯(0),
that is, u(ρ;η) ∈ R which implies ϕ(R) ⊂ R. Hence by Brouwer’s Fixed Point Theorem there
exists η0 ∈ R such that η0 = ϕ(η0), i.e. u(0;η0) = u(ρ;η0). Therefore by [8, Lemma 2.2.1] for
initial condition u(0) = η0 the solution u(t) must be ρ-periodic and from (27) that solution must
be strictly positive. 
4.3. Special periodic solutions of the full system. We now classify all the special periodic so-
lutions to system (7) and determine the stability of each solution. With a slight abuse of notation,
the special periodic solutions are of the form:
PS1. (0, 0, 0, u4(t));
PS2. (u1(t), 0, 0, u4(t));
PS3. (0, u2(t), u3(t), u4(t));
PS4. (u1(t), u2(t), u3(t), u4(t)).
Here, uj(t+ ρ) = uj(t) > 0 for all t ≥ 0 and j = 1, 2, 3, 4.
4.3.1. PS1. For PS1 we see that u4 satisfies the ODE
du4
dt
= β4[i(t)− u4].
From Lemma B.1 we deduce that this has the ρ-periodic solution u4(t) = w(t;β4i, β4) for all
t ∈ R+ with initial condition given by (31).
4.3.2. PS2. For PS2 we see that u1 and u2 satisfy the system of equations
du1
dt
= u1(1− u1), du4
dt
= β4[i(t)− u4].
Since the equation for u1 is autonomous, the only nontrivial periodic solution is u1(t) = 1 for all
t ∈ R+. Again from Lemma B.1 we conclude that the u4 equation has ρ-periodic solution u4(t) =
w(t;β4i, β4) for all t ∈ R+ with initial condition given by (31).
4.3.3. PS3. For PS3 the system of ODEs is
du2
dt
= β2u2(1− u2 − δ2u4),
du3
dt
= β3(u2 − u3),
du4
dt
= β4[i(t)− u4 − δ4u2u4].
It suffices to consider the reduced system (12) since from Lemma B.1, if u2 is positive and ρ-
periodic, then a positive ρ-periodic solution of the u3 equation is u3(t) = w(t;β3u2, β3) for all
t ∈ R+ with initial condition given by (31). From Theorem 4.1 we know that there exists a unique
strictly positive ρ-periodic solution (u2, u4) to (12) if δ2 < 1.
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4.3.4. PS4. For PS4 the system of ODEs is
du1
dt
= u1(1− u1 − α1u2 − δ1u3),
du2
dt
= β2u2(1− u2 − α2u1 − δ2u4),
du3
dt
= β3(u2 − u3),
du4
dt
= β4[i(t)− u4 − δ4u2u4].
From Theorem 4.3 it is known there exists a strictly positive ρ-periodic solution to this system if
δ2 < 1, 1− (α1 + δ1)uˆ2+ > 0, 1 < (>)α1(1− δ2) and 1− δ2 < (>)α2.
4.4. Stability of special periodic solutions to the full system. We begin by determining the sta-
bility of PS1. Recall that PS1 is (0, 0, 0, u4(t)), where u4(t) = w(t;β4i, β4). Linearising (7) about
PS1, we obtain
dy
dt
=

1 0 0 0
0 β2[1− δ2u4(t)] 0 0
0 β3 −β3 0
0 −β4δ4u4(t) 0 −β4
y.
This has a fundamental matrix Φ(t) = (φij(t))1≤i,j≤4 given by
Φ(t) =

et 0 0 0
0 eβ2
∫ t
0 [1−δ2u4(s)] ds 0
0 β3
∫ t
0 e
−β3(t−s)φ22(s) ds e−β3t 0
0 −β4δ4
∫ t
0 e
−β4(t−s)u4(s)φ22(s) ds 0 e−β4t
 .
Since this matrix is lower triangular, the characteristic multipliers (i.e. the eigenvalues of Φ(ρ))
are
eρ, eβ2
∫ ρ
0 [1−δ2u4(s)] ds, e−β3ρ, e−β4ρ.
As |eρ| > 1, we conclude that PS1 is unstable.
Next we consider the stability of PS2, given by (1, 0, 0, u4(t)), where u4(t) = w(t;β4i, β4).
Linearising (7) about PS2 gives
dy
dt
=

−1 −α1 −δ1 0
0 β2[1− α2 − δ2u4(t)] 0 0
0 β3 −β3 0
0 −β4δ4u4(t) 0 −β4
y.
With a slight abuse of notation, a fundamental matrix Φ(t) = (φij(t))1≤i,j≤4 is
Φ(t) =

e−t − ∫ t0 e−(t−s)[α1φ22(s) + δ1φ32(s)] ds −δ1 ∫ t0 e−(t−s)e−β3sds 0
0 eβ2
∫ t
0 [1−α2−δ2u4(s)] ds 0 0
0 β3
∫ t
0 e
−β3(t−s)φ22(s) ds e−β3t 0
0 −β4δ4
∫ t
0 e
−β4(t−s)u4(s)φ22(s) ds 0 e−β4t
 .
The characteristic multipliers are then
e−ρ, eβ2
∫ ρ
0 [1−α2−δ2u4(s)] ds, e−β3ρ, e−β4ρ.
Thus the stability properties of PS2 will depend on the sign of
∫ ρ
0 [1−α2− δ2u4(s)] ds. Note that
the ODE for u4 in PS2 is
du4
dt
= β4[i(t)− u4(t)].
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Integrating from 0 to ρ gives ∫ ρ
0
u4(s) ds =
∫ ρ
0
i(s) ds = ρ,
so that ∫ ρ
0
[1− α2 − δ2u4(s)] ds = (1− α2)ρ− δ2ρ = ρ(1− α2 − δ2).
Therefore if α2 + δ2 > 1, then PS2 is stable. On the other hand, if α2 + δ2 < 1, then PS2 is
unstable.
Finally, we look at the stability of PS3. Recall that PS3 is of the form (0, u2(t), u3(t), u4(t)),
where (u2(t), u4(t)) is a periodic solution of (12) and u3(t) = w(t;β3u2, β3). Linearising (7)
about PS3 gives
(28)
dy
dt
= A(t)y,
where
A(t) =

1− α1u2(t)− δ1u3(t) 0 0 0
−α2β2u2(t) β2[1− 2u2(t)− δ2u4(t)] 0 −β2δ2u2(t)
0 β3 −β3 0
0 −β4δ4u4(t) 0 −β4[1 + δ4u2(t)]
 .
Let Θ(t) = (θij(t))1≤i,j≤3 be the fundamental matrix that satisfies Θ′ = C(t)Θ′; Θ(0) = I ,
where C(t) = (aij(t))2≤i,j≤4. Define
γ(t) = Θ(t)
∫ t
0
Θ−1(s)ζ(s) ds, where ζ(t) =
[
a21(t)e
∫ t
0 a11(s) ds 0 0
]T
.
Furthermore, let Ψ(t) = (ψij(t))1≤i,j≤2 be a fundamental matrix solution of (20), then the funda-
mental matrix solution of (28) is
Φ(t) =

e
∫ t
0 [1−α1q2(s)−δ1q3(s)] ds 0 0 0
γ1(t) ψ11(t) 0 ψ12(t)
γ2(t) β3eβ3t
∫ t
0 ψ11(t)e
β3s ds e−β3t β3eβ3t
∫ t
0 ψ12(t)e
β3s ds
γ3(t) ψ21(t) 0 ψ22(t)
 .
The characteristic multipliers are then e
∫ ρ
0 [1−α1u2(s)−δ1u3(s)] ds, e−β3ρ and the eigenvalues of
Ψ(ρ) which were shown in Section 4.1.3 to have modulus less that 1 if δ2 < 1. It is clear that
|e−β3ρ| < 1, hence it is required that
|e
∫ ρ
0 [1−α1u2(s)−δ1u3(s)] ds| < (>)1 ⇐⇒
∫ ρ
0
[1− α1u2(s)− δ1u3(s)] ds < (>)0
for the solution PS3 to be stable (unstable). From Lemmata B.1 and B.3∫ ρ
0
[1− α1u2(s)− δ1u3(s)] ds =
∫ ρ
0
[1− (α1 + δ1)u2(s)] ds ≥ ρ[1− (α1 + δ1)uˆ2+],
therefore if 1− (α1 + δ1)uˆ2+ > 0, then the solution is unstable. Now, from (12) it can be shown
that
1
ρ
∫ ρ
0
u2(s) ds = 1− δ2 1
ρ
∫ ρ
0
u4(s) ds.
Furthermore, by the periodicity of u4 and the positivity of u2 and u4, it can be obtained from (12)
that
1
ρ
∫ ρ
0
u4(s) ds = 1− 1
ρ
∫ ρ
0
u2(s)u4(s) ds < 1
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and as a result we can conclude
1
ρ
∫ ρ
0
1− α1u2(s)− δ1u3(s) ds = 1− (α1 + δ1)1
ρ
∫ ρ
0
u2(t) ds
= 1− (α1 + δ1)
(
1− δ2 1
ρ
∫ ρ
0
u4(t) ds
)
< 1− (α1 + δ1)(1− δ2) < 0
if δ2 < (α1+δ1−1)/(α1+δ1). Noting that (α1+δ1−1)/(α1+δ1) < 1, it can then be concluded
that if δ2 < (α1 + δ1 − 1)/(α1 + δ1), then PS3 is a stable.
5. Discussion
It is first noted that the results obtained for the model proposed by Byrne [1], corresponding to
system (12), have been further extended, that is, an examination of the behaviour of the model when
i(t) is an arbitrary continuous-time-periodic function has been presented. In the analysis conducted
by Byrne [1], i was given by (8) and it was assumed that x2 ≡ i and then (12) reduced to a single
Bernoulli equation that could be readily solved. Here, no assumptions were made about x2, rather
the model was considered for all i ∈ C(R+, [0, iM ]), where i(t) = i(t + ρ) for some ρ > 0 and
t ∈ R+. It was found that there exist ρ-periodic solutions to (12) that were stable for different
parameter values. The trivial tumour-tissue free solution (i.e. x1 ≡ 0) was found to exist for all
parameter values andwas found to be asymptotically stable for δ2 > 1 and unstable for δ2 < 1. This
is the same result observed for the analogous SS (i.e. RS1) of the model using the constant infusion
function. Hence this suggests that using a different method of drug delivery will not change the
conditions in which the tumour can be removed from the system, rather it is only required that the
same total amount of drug is delivered over each treatment period. For system (12) a ρ-periodic
solution of the form x(t) =
[
x1(t) x2(t)
]T
> 0 was found to exist for δ2 < 1. Furthermore, this
solution was shown to be asymptotically stable if δ2 < 1. It is also noted that if δ2 > (1+δ4)2/4δ4,
then no ρ-periodic solution of this form can exist, as is the case for the analogous SS of the constant
infusion model (i.e. RS2). It was also shown that if 1 ≤ δ2 ≤ (1 + δ4)2/4δ4 and δ4 < 1, then no
biologically meaningful ρ-periodic solution of this form could exist. Once again, this condition is
the same as for the analogous SS of the constant infusion model.
Considering the trivial periodic solution given by PS1, this solution, as in the constant infusion
model, is unconditionally unstable and as a result this suggests that the model should always con-
tain normal-tissue or tumour-tissue. This behaviour is to be expected and is consistent with cell
models. The less trivial state PS2, that represents the tumour-free state, is shown to be stable when
α2 + δ2 > 1 (similarly, unstable if α2 + δ2 < 1). Note that this is the condition for stability of
the analogous SS in the constant infusion case (i.e. SS2). Whilst it should naturally follow that the
periodic stability conditions should imply when the SSs of the constant infusion model are stable
(respectively, unstable), it should be noted that these conditions are independent of i(t) and are
identical for all non-negative continuous periodic functions. Hence these conditions suggest that
for the normal-tissue to remain within the system, at the least, there needs to be sufficiently strong
population competition and treatment strength. Should there not be significant competition pro-
vided by the normal-tissue or large enough treatment strength cannot be obtained, for example, if
the required dose to do so is unsafe, then this state will be unstable and this would provide the ideal
conditions for tumour invasion. Hence if the competition that is provided by the normal-tissue is
able to be increased, then this would enable the tumour-free solution to become stable and improve
the potential efficacy of the treatment. It is clear from this result alone that population competition
has a potentially important role to play in treating tumour invasion. Furthermore, if a treatment
somehow indirectly weakens the effective competition that normal-tissue can provide without low-
ering the tumour-tissue competition a proportional amount, then this can actually be harmful to the
potential efficacy of the treatment. In a case like this, the assessment would need to be made of
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whether the relative benefit gained in fighting the tumour with the specific treatment outweighs the
loss incurred from the damaged competition that the normal-tissue provides.
The normal-tissue free periodic solution (i.e. PS3) was shown to exist if δ2 < 1 and furthermore
could not exist if δ2 > (1 + δ4)2/4δ4, or if 1 ≤ δ2 < (1 + δ4)2/4δ4 and δ4 ≤ 1. Hence this
represents the parameter condition in which it can be assured that an invasive tumour will not
exist. In this state, the concentration of chemotherapy drug is lower than the tumour-free state,
as would be expected due to the model assumption that interaction with the tumour causes some
portion of the drug to decay. From the stability analysis in Section 4.4, it can be seen that the
normal-tissue free periodic solution is unstable if
1− (α1 + δ1)uˆ2+ > 0.
Hence there is a sufficiently large treatment strength that needs to be obtained in order prevent this
invasive normal-tissue free state from being able to invade. Furthermore, from this condition it can
be concluded that should α1+δ1 ≤ 1, then the state is unstable. Therefore if the combined strength
of the tumour-tissue competition and the destructive influence of the acid is low, then the tumour
will not be invasive. This is consistent with the results obtained for the constant infusion model
considered in Section 3 and for the heterogeneous model considered by McGillen et al. [17]. This
further demonstrates the potential importance of the acid-mediation hypothesis, in that, should a
tumour provide low population competition, then invasion may still be achieved provided a suffi-
ciently strong destructive influence of the acid. This once again is consistent with the results of the
model proposed by McGillen et al. [17].
It was shown in Section 4.4 that if δ2 < (α1 + δ1 − 1)/(α1 + δ1), then the normal-tissue free
solution (i.e. PS3) is asymptotically stable. Hence for sufficiently small treatment strength and
sufficiently large tumour population competition and tumour aggressiveness, the invasive tumour
state will be stable. It should be noted that the normal-tissue free solution could still be stable
for larger values of δ2, however the conducted analysis was unable to confirm stability for values
of δ2 outside of this set of values. If the normal-tissue population competition is sufficiently low,
then the invasive tumour state will be the only stable solution. This will result in the tumour suc-
cessfully invading and the treatment being unsuccessful. If however the normal-tissue population
competition is sufficiently strong, i.e. if α2 + δ2 > 1, then the tumour-tissue free solution will be
stable and hence the system will be bistable. Should this be the case, the size of the initial tumour
will alter the efficacy of the treatment protocol which, as expected, is consistent with the results
of the constant infusion model and the decreased likelihood of a cure associated with more estab-
lished tumours [19]. From this it can be seen that the population competition, that is, the relative
interaction between different cell types, can have a significant impact on the efficacy of the tumour
treatment.
It was shown that a strictly positive ρ-periodic coexistence solution exists for (7) (i.e. PS4).
Moreover, numerical simulations, using (8) for i, suggest that this solution is stable for particu-
lar parameter values. It is noted that this state exists and moreover, is stable, when the tumour
aggressiveness, tumour-tissue population competition, normal-tissue population competition and
destructive influence of the chemotherapy is low (i.e. δ1, α1, α2, δ2 are “small”). This is consistent
with the results obtained for the constant infusion model. Should any of these parameters increase,
the properties of the model change dramatically. If the tumour aggressiveness increases, then the
tumour would become invasive as the normal-tissue free periodic solution would become stable
while the tumour-tissue free solution would remain unstable. Conversely, should the destructive
influence of the chemotherapy be increased, by way of increased drug infusion (say), the coex-
istence state would be come unstable and the tumour-free periodic solution would become stable
resulting in the tumour being removed from the system.
6. Concluding remarks
A model for the acid-mediation hypothesis in the presence of a chemotherapy treatment has
been proposed and considered. The proposed model is a simple ODE model that is comprised
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of the normal-tissue, tumour-tissue, acid concentration, and chemotherapy drug concentration in
a homogeneous setting. The model was based on the model proposed by McGillen et al. [17] in
combination with that proposed by Byrne [1] and has been considered to obtain an understanding
of the reaction dynamics governing the system and to provide insights required before considering
this in a heterogeneous setting. The model was considered mathematically for different treatment
methods using both numerical and analytical techniques.
The model has been considered with constant drug infusion which produced an autonomous sys-
tem that was studied using a steady state analysis. The model was also considered assuming the use
of treatment occurring in cycles, which was characterised by time-periodic infusion functions. This
resulted in a non-autonomous system that could be examined using an analysis of time-periodic so-
lutions. The results from each analysis draw similar, if not the same, conclusions about the effect
of competition, the treatment strength and the destructive influence of acid on the overall system
dynamics. This suggests that the method of drug delivery is not a significant factor when trying to
treat a tumour, rather it is the average rate of delivery which is the important factor. Hence much
more focus can be placed on ensuring the safest method of delivery is used. Moreover, from a
modelling stand point this suggests, at least in a homogeneous model, that the choice of infusion
function is not as influential to the overall behaviour of the system as may be intuitively thought.
This however only relates to the long term behaviour of the system, whereas the short term dy-
namics may still vary largely based on the choice of infusion function. Furthermore, this does not
consider the potential dynamics that could be displayed in a heterogeneous setting in which spatial
variation and associated mechanisms must be considered.
Since the model considered in this article assumes homogeneous populations, that is, well mixed
populations, there are natural limitations to the conclusions that can be drawn from this analysis.
However analysis conducted of this homogeneous model provides insights into the potential long-
term behaviour of a heterogeneous version of this model, particularly in the situations of monos-
table solutions for the system. Hence analysis of a model that considers a heterogeneous setting
will be considered in a following article to further understand the dynamics of the acid-mediation
hypothesis with chemotherapy intervention.
Appendix A. Auxiliary definitions and results
We include for the convenience of the reader a collection of definitions and results required for
this article.
Definition A.1 (Quasimonotonicity, see [21, §10, XII]). The function F : D ⊂ Rn+1 → Rn is
said to be quasimonotone increasing on D if for i = 1, . . . , n,
u ≤ v, ui = vi, (t,u), (t,v) ∈ D =⇒ Fi(t,u) ≤ Fi(t,v).
Remark A.2. A matrix C = (cij) is said to be essentially positive if cij ≥ 0 for all i 6= j. A
function F : D ⊂ Rn+1 → Rn is quasimonotone increasing on a set D ⊂ Rn+1 if the Jacobian
matrix F′u(t,u) is essentially positive for all (t,u) ∈ D.
Definition A.3 (Invariant Sets in Rn, see [21, §10, XV]). A set D ⊂ Rn is said to be invariant
with respect to the system u′ = F(t,u) if for any solution u, u(t0) ∈ D implies u(t) ∈ D for
t > t0 (as long as the solution exists).
Definition A.4 (Tangent Condition, see [21, §10, XV]). LetD ⊂ Rn and F : E ⊃ J ×D → Rn,
where J ⊂ R is an interval. The tangent condition is given by
〈n(u),F(t,u)〉 ≤ 0, for t ∈ J, u ∈ ∂D,
where n(u) is the outer normal to D at u.
Definition A.5 (Local Lipschitz Condition, see [21, §6, IV]). Let J ⊂ R,D ⊂ Rn andE = J×D.
Then the function F : E → Rn is said to satisfy a local Lipschitz condition with respect to u in E
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if for every (t0,u0) ∈ E there exists a neighbourhood U = U(t0,u0) and an L = L(t0,u0) <∞
such that for all (t,u1), (t,u2) ∈ U ∩ E the function F satisfies the Lipschitz condition
‖F(t,u1)− F(t,u2)‖ ≤ L‖u1 − u2‖.
Remark A.6. If D is open and if F ∈ C(E,Rn) has continuous derivative F′u(t,u) in E, then F
satisfies a local Lipschitz condition with respect to u in E.
Theorem A.7 (Invariance Theorem, see [21, §10, XVI]). Let D ⊂ Rn be closed, F : [t0,∞) ×
D → Rn bounded and continuous and consider the system u′ = F(t,u). Suppose that F satisfies
the tangent condition (see Definition A.4) and the one-sided Lipschitz condition on D, that is
〈u1 − u2,F(t,u1)− F(t,u2)〉 ≤ L‖u1 − u2‖2 for all t ∈ [t0,∞), u1,u2 ∈ D.
Then for any u(t0) ∈ D a unique solution u(t) exists for all t ∈ [t0,∞) which is invariant on D.
Theorem A.8 (Comparison Theorem, see [21, §10, Comparison Theorem]). Let D ⊂ Rn and
J = [t0, t0 + a]; assume that F : J × D → Rn is quasimonotone increasing and that F(t,u)
satisfies a local Lipschitz condition with respect to u in J × D. Suppose that u′ = F(t,u) and
v′ ≤ F(t,v), if u(t) and v(t) are differentiable on J and v(t0) ≤ u(t0), then v(t) ≤ u(t) for all
t ∈ J .
As a consequence of Theorem A.8 we have the following corollary.
Corollary A.9. LetD ⊂ Rn, J = [t0, t0 + a] and F : J ×D → Rn; assume that F(t,u) satisfies
a local Lipschitz condition with respect to u on J ×D and that u satisfies u′ = F (t,u). Suppose
that there exists an invertible n× n matrixM such thatMv′ ≤MF(t,v) andMF(t,M−1η) is
quasimonotone increasing on J × {η ∈ Rn : M−1η ∈ D}. If u(t) and v(t) are differentiable on
J andMv(t0) ≤Mu(t0), thenMv(t) ≤Mu(t) for all t ∈ J .
Proof. It is well known that for any linear operator T : Ω ⊂ Rn → Rn there exists a constant
c ∈ R such that ‖Tx‖ ≤ c‖x‖ for all x ∈ Ω [21, p. 58]. Hence there exists c ∈ R such
that ‖MF(t,u1) −MF(t,u2)‖ = ‖M(F(t,u1) − F(t,u2))‖ ≤ c‖F(t,u1) − F(t,u2)‖ for all
(t,u1), (t,u2) ∈ J ×D. Then as F(t,u) satisfies a local Lipschitz condition on J ×D it easily
follows that so too doesMF(t,u).
Let u¯(t) = Mu(t) and v¯(t) = Mv(t), thenwe have u¯′ = MF(t,M−1u¯) and v¯′ ≤MF(t,M−1v¯)
on J × E, where E = {η ∈ Rn : M−1η ∈ D}. NoteMF(t,M−1u¯) is quasimonotone increas-
ing on J × E and if u(t) and v(t) are differentiable on J , so too are u¯(t) and v¯(t). Therefore by
Theorem A.8 if v¯(t0) ≤ u¯(t0), then v¯(t) ≤ u¯(t) for all t ∈ J , that is, ifMv(t0) ≤Mu(t0), then
Mv(t) ≤Mu(t) for all t ∈ J . 
Appendix B. Results for specific ODEs and corresponding periodic solutions
Lemma B.1. Consider the equation
(29)
dw
dt
= f(t)− g(t)w,
where f, g ∈ C(R+) are ρ-periodic. Suppose that∫ ρ
0
g(s) ds 6= 0, f(t) ≥ (>)0 for all t ∈ R+.
Then the following statements hold:
(i) The function
(30) w(t; f, g) = w(0)e−
∫ t
0 g(s) ds +
∫ t
0
e−
∫ t
s g(s
′) ds′f(s) ds
is the unique solution of (29) for any initial condition w(0) ∈ R. Note that w(t; f, g) > 0
for all t ≥ 0 if and only if w(0) > 0.
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(ii) If
(31) w(0) =
∫ ρ
0 e
− ∫ ρs g(s′) ds′f(s) ds
1− e−
∫ ρ
0 g(s) ds
,
then (30) is the unique ρ-periodic solution, where∫ ρ
0
g(t)w(t) dt =
∫ ρ
0
f(t) dt.
Moreover, w(0) ≥ (>)0 if and only if ∫ ρ0 g(s) ds > 0.
(iii) Suppose that g1(t) ≥ g2(t) for all t ∈ R+ and
∫ ρ
0 g2(s) ds > 0. If w(t; f, g1) and
w(t; f, g2) have initial conditions given by (31), then w(t; f, g1) ≤ w(t; f, g2) for all t ∈
R+.
Proof. (i) The unique solution w = w(·; f, g) of the linear ODE (29) for any initial condition
is given by (30). Since f(t) ≥ 0 for all t ∈ R+ it is straightforward to see that w(t; f, g) >
0 for all t ≥ 0 if and only if w(0) > 0.
(ii) If the initial condition is given by (31), then w(ρ) = w(0). Furthermore, the ρ-periodicity
of f and g implies that
w′(t) = f(t)− g(t)w(t), w′(t+ ρ) = f(t)− g(t)w(t+ ρ) for all t ≥ 0.
Then w¯(t) = w(t+ ρ)− w(t) satisfies the initial value problem
dw¯
dt
= −g(t)w¯, w¯(0) = 0.
Hence w¯ ≡ 0 andw(t+ρ) = w(t) for all t ≥ 0. Since f(t) ≥ (>)0 for all t ∈ R+ it is clear
that ifw(0) is given by (31), thenw(0) ≥ (>)0 if and only if ∫ ρ0 g(s) ds > 0. To show that
the solution for (31) is the unique ρ-periodic solution we consider two distinct ρ-periodic
solutions for (29) denoted by w1(t) and w2(t). Due to uniqueness to initial conditions
w1(t) 6= w2(t) for all t ∈ R+, so without loss of generality we assume w1(t) > w2(t) for
all t ∈ R+. Then ε(t) = w1(t)− w2(t) = w1(t+ ρ)− w2(t+ ρ) = ε(t+ ρ) > 0 for all
t ∈ R+ satisfies
dε
dt
= −g(t)ε =⇒ 0 =
∫ ρ
0
1
ε(s)
dε
ds
ds = −
∫ ρ
0
g(s) ds,
which is a contradiction. Therefore the ρ-periodic solution for initial condition (31) must
be unique.
(iii) Suppose that g1(t) ≥ g2(t) for all t ∈ R+ and
∫ ρ
0 g2(s) ds > 0, then
∫ ρ
0 g1(s) ds ≥∫ ρ
0 g2(s) ds > 0. If w(t; f, g1) and w(t; f, g2) have initial conditions given by (31), then
w(t; f, g1) and w(t; f, g2) are unique ρ-periodic solutions and w(t; f, g1), w(t; f, g2) ≥ 0
for all t ∈ R+. Let ε(t) = w(t; f, g2)−w(t; f, g1) = w(t+ ρ; f, g2)−w(t+ ρ; f, g1) =
ε(t+ ρ) which satisfies
ε′ = [g1(t)− g2(t)]w(t; f, g2)− g1(t)ε.
Now [g1(t) − g2(t)]w(t; f, g2) ≥ 0 for all t ∈ R+, hence by the previous results the
ρ-periodic solution ε(t) ≥ 0 for all t ∈ R+, i.e. w(t; f, g1) ≤ w(t; f, g2) for all t ∈ R+.

Lemma B.2. Consider the equation
(32)
dv
dt
= g(t)v − f(t)v2,
where f, g ∈ C(R+) are ρ-periodic. Suppose that∫ ρ
0
g(s) ds 6= 0, f(t) > 0 for all t ∈ R+.
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Then the following statements hold:
(i) The function
(33) v(t; f, g) =
[
v(0)−1e−
∫ t
0 g(s) ds +
∫ t
0
e−
∫ t
s g(s
′) ds′f(s) ds
]−1
is the unique solution of (32) for any initial condition v(0) > 0. Note that v(t; f ; g) > 0
for all t ∈ R+ if and only if v(0) > 0.
(ii) If
∫ ρ
0 g(s) ds > 0 and
(34) v(0) =
1− e−
∫ ρ
0 g(s
′) ds′∫ ρ
0 e
− ∫ ρs g(s′) ds′f(s) ds,
then (33) is a unique strictly positive ρ-periodic solution. Moreover, v(0) > 0 if and only
if
∫ ρ
0 g(s) ds > 0.
(iii) Suppose that g1(t) ≥ g2(t) for all t ∈ R+ and
∫ ρ
0 g2(s) ds > 0. If v(t; f, g1) and v(t; f, g2)
have initial conditions given by (34), then v(t; f, g1) ≥ v(t; f, g2) for all t ∈ R+.
Proof. (i) Set v = v(·; f, g) in the Bernoulli equation (32) to v(t) = u(t)−1. Then u satisfies
the linear ODE
du
dt
= f(t)− g(t)u,
whose solution for any initial condition is
u(t) = u(0)e−
∫ t
0 g(s) ds +
∫ t
0
e−
∫ t
s g(s
′) ds′f(s) ds.
Hence (33) follows.
(ii) Since f(t) > 0 for all t ∈ R+ it is clear that if v(0) is given by (34), then v(0) > 0 if and
only if
∫ ρ
0 g(s) ds > 0. If
∫ ρ
0 g(s) ds > 0 and the initial condition is given by (34), then
u(ρ) = u(0) > 0 and a similar analysis as in the proof of Lemma B.1 shows that v is a
unique strictly positive ρ-periodic solution.
(iii) Suppose that g1(t) ≥ g2(t) for all t ∈ R+ and
∫ ρ
0 g2(s) ds > 0. If the initial conditions for
v(t; f, g1) and v(t; f, g2) are given by (34), then Lemma B.1(iii) shows that u(t; f, g1) ≤
u(t; f, g2) for all t ∈ R+, which implies v(t; f, g1) ≥ v(t; f, g2) for all t ∈ R+.

Lemma B.3. Suppose that there exists a solution x(t) =
[
x1(t) x2(t)
]T
> 0 for all t ∈ R+ to
system (12), then it follows that
δ4x1(t)
2 + (1− δ4)x1(t) + δ1i(t)− 1 = d
dt
V (x(t)),
where V (x) = −(δ4/β2)x1 + (δ2/β4)x2 − (1/β2) lnx1. Moreover, it is a necessary condition
that
δ2i(t)− ddtV (x(t)) ≤
(1 + δ4)
2
4δ4
.
If the solution is ρ-periodic, then
(i) The solution exists only if δ2 < 1 or only if 1 ≤ δ2 ≤ (1+δ4)2/4δ4 and δ4 > 1. Moreover,
0 ≤ 1
ρ
∫ ρ
0
x1(s) ds ≤ uˆ2+.
(ii) If δ2 < 1, then
x1(t) =
δ4 − 1 +
√
(δ4 + 1)2 − 4δ4[δ2i(t)− h(t)]
2δ4
,
where h(t) = ddtV (x(t)).
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Proof. We wish to find a function V = V (x) such that
d
dt
V (x(t)) = A(t)x1(t)
2 +B(t)x1(t) + C(t),
where A, B and C are appropriate ρ-periodic functions. Note the right-hand side is independent
of x2. By considering (12), we can try the ansatz
V (x) = ax1 + bx2 + c log x1,
where a, b and c are constants. Then
d
dt
V (x(t)) =
[
a+
c
x1(t)
]
x′1(t) + bx
′
2(t)
= − aβ2x1(t)2 + (a− c)β2x1(t) + cβ2 + bβ4i(t)
− (aβ2δ2 + bβ4δ4)x1(t)x2(t)− (cβ2δ2 + bβ4)x2(t).
To eliminate the terms involving x2, we set
a = − δ4
β2
, b =
δ2
β4
, c = − 1
β2
.
This gives
(35)
d
dt
V (x(t)) = δ4x1(t)
2 + (1− δ4)x1(t) + δ2i(t)− 1,
i.e. A(t) = δ4, B(t) = 1− δ4 and C(t) = δ2i(t)− 1. Rewriting (35), we obtain
x1(t) =
(δ4 − 1)±
√
(δ4 − 1)2 + 4δ4[1− δ2i(t) + h(t)]
2δ4
=
(δ4 − 1)±
√
(δ4 + 1)2 − 4δ4[δ2i(t)− h(t)]
2δ4
,
where h(t) = ddtV (u2(t), u4(t)). If x1(t) > 0 for all t ∈ R+, a necessary condition is that
(36) δ2i(t)− h(t) ≤ (δ4 + 1)
2
4δ4
.
Suppose that the solution x(t) > 0 is ρ-periodic:
(i) Integrating both sides of (36) with respect to t from 0 to ρ and using the periodicity of x,
we have
(δ4 + 1)
2
4δ4
≥ 1
ρ
∫ ρ
0
[δ2i(t)− h(t)] dt = δ2.
Moreover, by the Mean Value Theorem, there exists t∗ ∈ (0, ρ) such that
1
ρ
∫ ρ
0
[δ2i(t)− h(t)] dt = δ2i(t∗)− h(t∗).
We therefore deduce that
x1(t
∗) =
(δ4 − 1)±
√
(δ4 + 1)2 − 4δ4δ2
2δ4
,
which has at least one strictly positive value if and only if δ2 < 1, or if 1 ≤ δ2 ≤ (1 +
δ4)
2/4δ4 and δ4 > 1, hence if these parameter conditions are not satisfied, then it is not
possible for x1(t) > 0 for all t ∈ R+.
Moreover, the Cauchy-Schwarz inequality gives
1
ρ
∫ ρ
0
√
(δ4 + 1)2 − 4δ4[δ2i(s)− h(s)] ds ≤
[
1
ρ
∫ ρ
0
{(δ4 + 1)2 − 4δ4[δ2i(s)− h(s)]}ds
]1/2
=
√
(δ4 + 1)2 − 4δ4δ2.
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Hence
0 ≤ 1
ρ
∫ ρ
0
x1(s) ds ≤ max
{
1
ρ
∫ ρ
0
(δ4 − 1)±
√
(δ4 + 1)2 − 4δ4[δ2i(s)− h(s)]
2δ4
ds
}
≤ uˆ2+
(ii) If δ2 < 1, we further deduce that
(δ4 − 1)2 + 4δ4[1− δ2i(t∗) + h(t∗)] > (δ4 − 1)2
and as a result
x1(t) =
(δ4 − 1) +
√
(δ4 − 1)2 + 4δ4[1− δ2i(t) + h(t)]
2δ4
,
otherwise x1 can become negative at t∗.

Appendix C. Details of steady-state analysis
Lemma C.1. The system of equations given by (10) has the following SS solutions and respective
linear stability conditions:
SS1. u∗ = (0, 0, 0, 1) is unconditionally unstable.
SS2. u∗ = (1, 0, 0, 1) is stable if and only if α2 + δ2 > 1.
SS3. u∗ = (0, uˆ2±, uˆ2±, [1 + δ4uˆ2±]−1), where uˆ2± =
[
δ4 − 1±
√
(1 + δ4)2 − 4δ2δ4
]
/2δ4.
The SS corresponding to uˆ2− is unconditionally unstable and the SS corresponding to uˆ2+
will be stable if and only if
δ2 <
(α1 + δ1 + δ4)(α1 + δ1 − 1)
(α1 + δ1)2
,
or if
(α1 + δ1 + δ4)(α1 + δ1 − 1)
(α1 + δ1)2
≤ δ2 < (1 + δ4)
2
4δ4
and
1
δ4
<
α1 + δ1 − 2
α1 + δ1
.
SS4. u∗ = (1− [α1 + δ1]u˜2±, u˜2±, u˜2±, [1 + δ4u˜2±]−1), where
u˜2± =
−(1− α2(α1 + δ1))− δ4(α2 − 1)
2δ4(1− α2(α1 + δ1))
±
√
[1− α2(α1 + δ1)− δ4(α2 − 1)]2 − 4δ2δ4(1− α2(α1 + δ1))
2δ4(1− α2(α1 + δ1)) .
The SS corresponding to u˜2− has no biologically meaningful values for which it is stable.
The SS corresponding to u˜2+ is stable if and only if
0 < (α1 + δ1)u˜2+ < 1, 0 < δ2 <
[1− α2(α1 + δ1)− δ4(α2 − 1)]2
4δ4[1− α2(α1 + δ1)]
and
c1c2c3 > c
2
3c0 + c
2
1,
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where
c3 = 1− (α1 + δ1)u˜2 + β3 + β2u˜2 + β4(1 + δ4u˜2),
c2 =β3[β2u˜2 + β4(1 + δ4u˜2)] + [1− (α1 + δ1)u˜2][β3 + β4(1 + δ4u˜2) + β2u˜2(1− α2α1)]
+
β2β4u˜2
1 + δ4u˜2
[(1 + δ4u˜2)
2 − δ2δ4],
c1 = [1− (α1 + δ1)u˜2]
[
β2β4u˜2
1 + δ4u˜2
[(1 + δ4u˜2)
2(1− α2α1)− δ2δ4] + β3β4(1 + δ4u˜2)
]
+ β2β3u˜2[1− (α1 + δ1)u˜2][1− α2(α1 + δ1)] + β2β3β4u˜2
1 + δ4u˜2
[(1 + δ4u˜2)
2 − δ2δ4],
c0 =
β2β3β4u˜2
1 + δ4u˜2
[1− (α1 + δ1)u˜2]
[
(1 + δ4u˜2)
2(1− α2(α1 + δ1))− δ2δ4
]
.
Proof. We consider the system of equations given by (10), set the derivatives to zero (i.e u′ = 0)
and solve for u1, u2, u3, u4 to obtain the SS solutions. We obtain the solutions
(0, 0, 0, 1), (1, 0, 0, 1),
(
0, uˆ2, uˆ2,
1
1 + δ4uˆ2
)
,
(
1− (α1 + δ1)u˜2, u˜2, u˜2, 1
1 + δ4u˜2
)
,
where uˆ2 solves
(37) δ4uˆ22 + (1− δ4)uˆ2 + δ2 − 1 = 0
and u˜2 solves
(38) δ4[1− α2(α1 + δ1)]u˜22 + [1− α2(α1 + δ1) + δ4(α2 − 1)]u˜2 + δ2 + α2 − 1 = 0.
We wish to determine the stability of these solutions by performing a linear stability analysis.
Consider the following vector:
F(u) =

u1(1− u1 − α1u2 − δ1u3)
β2u2(1− u2 − α2u1 − δ2u4)
β3(u2 − u3)
β4(1− u4 − δ4u4u2)
 .
The Jacobian matrix of F is then given by
F′u(u) =

1− 2u1 − α1u2 − δ1u3 −α1u1 −δ1u1 0
−β2α2u2 β2(1− 2u2 − α2u1 − δ2u4) 0 −β2δ2u2
0 β3 −β3 0
0 −β4δ4u4 0 −β4(1 + δ4u2)

SS1. Now if we consider the SS solution (0, 0, 0, 1) we have the Jacobian matrix
F′u(0, 0, 0, 1) =

1 0 0 0
0 β2(1− δ2) 0 0
0 β3 −β3 0
0 −β4δ4 0 −β4

which has eigenvalues λ = 1, β2(1− δ2),−β3,−β4. Hence we can see this is unstable for
all parameter values as λ = 1 > 0.
SS2. The SS (1, 0, 0, 1) has Jacobian matrix
F′u(1, 0, 0, 1) =

−1 −α1 −δ1 0
0 β2(1− α2 − δ2) 0 0
0 β3 −β3 0
0 −β4δ4 0 −β4

with eigenvalues λ = −1, β2(1 − α2 − δ2),−β3,−β4. Therefore we can see that all
Re(λ) < 0 if and only if α2 + δ2 > 1. Hence we have that (1, 0, 0, 1) is linearly stable if
α2 + δ2 > 1.
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SS3. We consider the SS solution u∗ = (0, uˆ2, uˆ2, [1 + δ4uˆ2]−1) noting from F(u) = 0 we
have 1− u2 − α2u1 − δ2u4 = 0. Hence we have the Jacobian matrix
F′u(u
∗) =

1− (α1 + δ1)uˆ2 0 0 0
−β2α2uˆ2 −β2uˆ2 0 −β2δ2uˆ2
0 β3 −β3 0
0 −β4δ4(1 + δ4uˆ2)−1 0 −β4(1 + δ4uˆ2)

with eigenvalues that satisfy λ = 1−(α1+δ1)uˆ2,−β3 and λ2+[β2uˆ2+β4(1+δ4uˆ2)]λ+
β2β4uˆ2[(1+δ4uˆ2)
2−δ4δ2]/(1+δ4uˆ2) = 0. Therefore using the Routh–Hurwitz conditions
[18, pp. 507–509], we have Re(λ) < 0 if 1 − (α1 + δ1)uˆ2 < 0, δ4δ2 < (1 + δ4uˆ2)2 and
uˆ2 > 0. Note that if 1 − (α1 + δ1)uˆ2 < 0, then it follows that uˆ2 > 0. Since uˆ2 satisfies
(37), we have that δ2 = 1− δ4uˆ22 + (δ4 − 1)uˆ2 and as a result
(1 + δ4uˆ2)
2 − δ4δ2 = (1 + δ4uˆ2)(2δ4uˆ2 + 1− δ4).
Therefore if 2δ4uˆ2 + 1− δ4 > 0, then it follows that δ4δ2 < (1 + δ4uˆ2)2. Consider (37),
solving for uˆ2 we obtain
uˆ2± =
δ4 − 1±
√
(1− δ4)2 + 4δ4(1− δ2)
2δ4
=
δ4 − 1±
√
(1 + δ4)2 − 4δ4δ2
2δ4
and note that uˆ2± ∈ R if and only if δ2 ≤ (1 + δ4)2/4δ4. Therefore
2δ4uˆ2± + 1− δ4 = ±
√
(1 + δ4)2 − 4δ4δ2
and as a result we can see that if δ2 < (1 + δ4)2/4δ4, then 2δ4uˆ2+ + 1 − δ4 > 0 and
2δ4uˆ2− + 1 − δ4 < 0. Hence SS3 with uˆ2− will be unstable for all parameter values and
we only require that 1−(α1+δ1)uˆ2+ < 0 for SS3 with uˆ2+ to be linearly stable. Consider
(α1 + δ1)uˆ2+ − 1
=
(α1 + δ1)(δ4 − 1)− 2δ4 + (α1 + δ1)
√
(1− δ4)2 + 4δ4(1− δ2)
2δ4
=
(α1 + δ1)(δ4 − 1)− 2δ4
2δ4
+
√
[(α1 + δ1)(δ4 − 1)− 2δ4]2 + 4δ4[(α1 + δ1 + δ4)(α1 + δ1 − 1)− δ2(α1 + δ1)2]
2δ4
Hence we can see that if
δ2 <
(α1 + δ1 + δ4)(α1 + δ1 − 1)
(α1 + δ1)2
,
then 1− (α1 + δ1)uˆ2+ < 0 and as a result SS3 with uˆ2+ is stable. If
(α1 + δ1 + δ4)(α1 + δ1 − 1)
(α1 + δ1)2
≤ δ2 < (1 + δ4)
2
4δ4
and
1
δ4
<
α1 + δ1 − 2
α1 + δ1
,
then 1− (α1 + δ1)uˆ2+ < 0 and as a result SS3 with uˆ2+ is linearly stable.
SS4. We consider the SS solution u∗ = (1 − (α1 + δ1)u˜2, u˜2, u˜2, [1 + δ4u˜2]−1) noting from
F(u) = 0 we have 1− u2 − α2u1 − δ2u4 = 0 and 1− u1 − α1u2 − δ1u3 = 0. Hence we
have the Jacobian matrix
F′u(u
∗) =

(α1 + δ1)u˜2 − 1 α1[(α1 + δ1)u˜2 − 1] δ1[(α1 + δ1)u˜2 − 1] 0
−β2α2u˜2 −β2u˜2 0 −β2δ2u˜2
0 β3 −β3 0
0 −β4δ4(1 + δ4u˜2)−1 0 −β4(1 + δ4u˜2)

that has a characteristic equation
λ4 + c3λ
3 + c2λ
2 + c1λ+ c0 = 0,
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where
c3 = 1− (α1 + δ1)u˜2 + β3 + β2u˜2 + β4(1 + δ4u˜2),
c2 =β3[β2u˜2 + β4(1 + δ4u˜2)] + [1− (α1 + δ1)u˜2][β3 + β4(1 + δ4u˜2) + β2u˜2(1− α2α1)]
+
β2β4u˜2
1 + δ4u˜2
[(1 + δ4u˜2)
2 − δ2δ4],
c1 = [1− (α1 + δ1)u˜2]
[
β2β4u˜2
1 + δ4u˜2
[(1 + δ4u˜2)
2(1− α2α1)− δ2δ4] + β3β4(1 + δ4u˜2)
]
+ β2β3u˜2[1− (α1 + δ1)u˜2][1− α2(α1 + δ1)] + β2β3β4u˜2
1 + δ4u˜2
[(1 + δ4u˜2)
2 − δ2δ4],
c0 =
β2β3β4u˜2
1 + δ4u˜2
[1− (α1 + δ1)u˜2]
[
(1 + δ4u˜2)
2(1− α2(α1 + δ1))− δ2δ4
]
From Routh–Hurwitz conditions [18, pp. 507–509], c0, c1, c2, c3 > 0 and c1c2c3 > c23c0+
c21 if and only if Re(λ) < 0. Hence we require c0, c1, c2, c3 > 0 and c1c2c3 > c23c0 + c21
for u˜2 to be linearly stable. Note that if
u˜2 > 0, 1− (α1 + δ1)u˜2 > 0 and 0 < δ2δ4 < (1 + δ4u˜2)2(1− α2(α1 + δ1)),
then c0 > 0. Note that
(1 + δ4u˜2)
2(1− α2(α1 + δ1)) < (1 + δ4u˜2)2(1− α2α1) < (1 + δ4u˜2)2,
hence these conditions will imply that c0, c1, c2, c3 > 0. Since u˜2 satisfies (38) we have
−δ2 = (1 + δ4u˜2)[(1− α2(α1 + δ1))u˜2 + α2 − 1].
Hence we can show that
(39) (1+δ4u˜2)2(1−α2(α1+δ1))−δ2δ4 = (1+δ4u˜2)[(1−α2(α1+δ1))(2δ4u˜2+1)+δ4(α2−1)],
and as a result
(40) c0 = β2β3β4u˜2 [1− (α1 + δ1)u˜2] [(1− α2(α1 + δ1))(2δ4u˜2 + 1) + δ4(α2 − 1)] .
Now consider (38) and solve for u˜2 to obtain
u˜2± =
−(1− α2(α1 + δ1))− δ4(α2 − 1)
2δ4(1− α2(α1 + δ1))
±
√
[1− α2(α1 + δ1) + δ4(α2 − 1)]2 − 4δ4(1− α2(α1 + δ1))(δ2 + α2 − 1)
2δ4(1− α2(α1 + δ1))
=
−(1− α2(α1 + δ1))− δ4(α2 − 1)
2δ4(1− α2(α1 + δ1))
±
√
[1− α2(α1 + δ1)− δ4(α2 − 1)]2 − 4δ2δ4(1− α2(α1 + δ1))
2δ4(1− α2(α1 + δ1)) ,
(41)
and note that u˜2± ∈ R if and only if
0 < δ2 ≤ [1− α2(α1 + δ1)− δ4(α2 − 1)]
2
4δ4[1− α2(α1 + δ1)] or 1− α2(α1 + δ1) < 0.
Using (41), we have
(1− α2(α1 + δ1))(2δ4u˜2± + 1) + δ4(α2 − 1)
= ±
√
[(1− α2(α1 + δ1))− δ4(α2 − 1)]2 − 4δ2δ4(1− α2(α1 + δ1))
(42)
and therefore when u˜2± ∈ R we have that (42) will be positive for u˜2+ and negative
for u˜2−. We first note from (42) and (39) that we require either u˜2− < 0 or u˜1− =
1 − [α1 + δ1]u˜2− < 0 so that c0 > 0. Hence we can conclude that there will be no
biologically meaningful values of SS4 with u˜2− that are stable. If 1 − α2(α1 + δ1) < 0,
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we can see that (39) is negative: noting that (42) will be positive for u˜2+ in this case then
(39) implies that 1+δ4u˜2+ < 0. Hence we can conclude that u˜2+ < 0 and as a result, from
(40) we have that c0 < 0 if 1−α2(α1+δ1) < 0 for u˜2+. Therefore if 1−α2(α1+δ1) < 0,
then SS4 with u˜2+ is unstable. If 1−α2(α1 + δ1) > 0 and u˜2+ < 0, then we can see from
(42) that (40) will be negative for u˜2+ and hence SS4 with u˜2+ will be unstable. Therefore
we can see that for SS4 with u˜2+ to be stable it is necessary that
u˜2+ > 0, 1− (α1 + δ1)u˜2+ > 0 and 0 < δ2 < [1− α2(α1 + δ1)− δ4(α2 − 1)]
2
4δ4[1− α2(α1 + δ1)] .

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